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The intracellular pathogen Mycobacterium tuberculosis causes 
tuberculosis. Enhanced intracellular survival (Eis) protein, secreted by M. 
tuberculosis, enhances survival of Mycobacterium smegmatis in 
macrophages. M. tuberculosis Eis was shown to suppress host immune 
defenses by negatively modulating autophagy, inflammation, and cell death 
through c-Jun N-terminal kinase (JNK)-dependent inhibition of reactive 
oxygen species generation. M. tuberculosis Eis was demonstrated to 
contribute to drug resistance by acetylating multiple amines of 
aminoglycosides. However, the mechanism of enhanced intracellular 
survival by M. tuberculosis Eis remains unanswered. Therefore, I have 
characterized both M. tuberculosis and M. smegmatis Eis proteins 
biochemically and structurally. I have discovered that M. tuberculosis Eis is 
an efficient N

-acetyltransferase, rapidly acetylating Lys55 of dual-
specificity protein phosphatase 16 (DUSP16)/mitogen-activated protein 
kinase phosphatase-7 (MKP-7), a JNK-specific phosphatase. In contrast, M. 
smegmatis Eis is more efficient as an N

-acetyltransferase. I also show that 
M. smegmatis Eis acetylates aminoglycosides as readily as M. tuberculosis 
 ii 
Eis. Furthermore, M. tuberculosis Eis, but not M. smegmatis Eis, inhibits 
lipopolysaccharide-induced JNK phosphorylation. This functional difference 
against DUSP16/MKP-7 can be understood by comparing the structures of 
two Eis proteins. The active site of M. tuberculosis Eis with a narrow 
channel appears to be more suitable for sequence-specific recognition of the 
protein substrate than the pocket-shaped active site of M. smegmatis Eis. I 
propose that M. tuberculosis Eis initiates the inhibition of JNK-dependent 
autophagy, phagosome maturation, and reactive oxygen species generation 
by acetylating Lys55 of DUSP16/MKP-7. My work thus provides new 
insights into the mechanism of suppressing host immune responses and 
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Nearly one-third of the world’s population is infected with 
Mycobacterium tuberculosis. This pathogenic bacterium causes tuberculosis, 
which claims the lives of millions of people every year (Dye and Williams, 
2010). Tuberculosis has also become a global health issue due to the 
increased incidences of multidrug-resistant and extensively drug-resistant 
strains of M. tuberculosis (Chiang et al., 2010). This makes a search for 
targets of new antituberculosis drugs urgent. M. tuberculosis is a highly 
successful human pathogen, surviving and multiplying within the human 
macrophage cells of the infected people (Dahl et al., 2001). Therefore, 
treatment of tuberculosis is difficult, requiring many months of taking a 
combination of antibiotics. M. tuberculosis has the ability to persist in the 
form of a long-term asymptomatic infection, referred to as latent tuberculosis 
(Lin and Flynn, 2010). Latent tuberculosis becomes activated, when the 
body’s immune system is weakened. As a result, tuberculosis is the major 
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cause of the deaths among immuno-compromised AIDS patients (Getahun et 
al., 2010).  
In mycobacterial infection, host innate immune responses may play a 
crucial role in early protection against M. tuberculosis infection, leading to 
establishment of effective adaptive immunity to tuberculosis (Jo et al., 2007). 
Additionally, mitogen-activated protein kinase (MAPK) pathways are 
activated by M. tuberculosis or its components and play an essential role in 
the regulation of innate immune signaling during mycobacterial infection (Jo 
et al., 2007). As intracellular survival of M. tuberculosis plays a central role 
in its pathogenesis (Wei et al., 2000), it is important to understand the 
survival strategies of this bacterium within macrophages. M. tuberculosis has 
evolved a number of highly effective survival strategies inside the 
macrophage (Meena and Rajni, 2010). The best characterized survival 
mechanism of M. tuberculosis is the inhibition of phagosomal maturation 
and autophagy, between which a functional overlap was suggested (Meena 
and Rajni, 2010; Ehrt and Schnappinger, 2009; Vergne et al., 2004; Vergne I, 
et al. 2006). Both processes involve several steps including fusion with 
lysosomes and a number of protein factors such as Beclin 1 and vacuolar 
sorting protein 34 (VPS34), the class III phosphatidylinositol 3-kinase (Kang 
et al. 2011). The identification and characterization of mycobacterial 
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proteins that play a role in facilitating intracellular survival remain a priority 
for the development of new antituberculosis drugs. 
The Rv2416c gene of M. tuberculosis H37Rv strain was found to 
enhance intracellular survival of Mycobacterium smegmatis (M. smegmatis) 
in the human macrophage-like cell line U-937 and thus it was designated as 
eis (enhanced intracellular survival) (Wei et al., 2000) (Figure 1). The 
expression of its protein product directly correlated with the enhanced 
mycobacterial survival in U-937 cells (Wei et al., 2000). The M. tuberculosis 
Eis protein is produced during human tuberculosis infection and is released 
into the culture medium (Dahl et al., 2001). The sigma factor SigA was 
shown to bind to the eis promoter in the W-Beijing strain of M. tuberculosis 
and the activation of the M. tuberculosis eis gene correlated with increased 
SigA levels and enhanced intracellular survival (Wu et al., 2009). Treatment 
of T-cells with M. tuberculosis Eis inhibited extracellular signal-regulated 
kinase 1/2 (ERK1/2), JAK pathway, and subsequent production of tumor 
necrosis factor- (TNF-) and interleukin-4 (IL-4) (Lella and Sharma, 2007). 
M. tuberculosis Eis negatively regulated the secretion of IL-10 and TNF- 
by primary human monocytes in response to infection with the pathogen 
(Samuel et al., 2007).  
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Recently, M. tuberculosis Eis was shown to suppress host innate 
immune defenses by negatively modulating inflammation, autophagy, and 
cell death in a redox-dependent manner (Shin et al., 2010). The reported data 
indicate that M. tuberculosis Eis plays an essential role in regulating both the 
early generation of reactive oxygen species (ROS) and inflammatory 
responses in macrophages (Shin et al., 2010). It was also found that 
abrogated production of both ROS and proinflammatory cytokines by M. 
tuberculosis Eis depends on its N-acetyltransferase domain in the N-terminus 
(Shin et al., 2010). Enhanced macrophage survival by M. tuberculosis Eis 
was found to occur through the regulation of ROS signaling, which was c-
Jun N-terminal kinase (JNK)-dependent but was not p38- or ERK1/2-
dependent (Shin et al., 2010). Forced expression of dual-specificity protein 
phosphatase 16 (DUSP16), also called MAPK phosphatase-7 (MKP-7), 
suppressed activation of MAPKs in COS-7 cells in the order of selectivity, 
JNK >> p38 > ERK, suggesting that DUSP16/MKP-7 works as a JNK-
specific phosphatase (Masuda et al., 2001). 
A bioinformatic analysis predicted that the M. tuberculosis Eis protein 
contains a single acetyltransferase domain of the GCN5-related N-
acetyltransferase (GNAT) superfamily in the amino terminus (Samuel et al.,  
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2007). The acetyltransferase domain is predicted to cover residues 9160 of 
the 408-residue protein and contains a variant of the characteristic sequence 
motif (V/I-x-x-x-x-Q/R-x-x-G-x-G/A) for acetyltransferases at positions 
between 93 and 103 (93VAPTHRRRGLL103) (Samuel et al., 2007; Neuwald 
and Landsman 1997) (Figure 2). Sequence numbering of M. tuberculosis Eis 
follows the current EXPASY UniProtKB/Swiss-Prot database; six residues 
1MPQSDS6 at the amino terminus are missing from other databases due to a 
different translation initiation at Val7. Increased expression of M. 
tuberculosis Eis due to a mutation in the promoter region of the eis gene 
conferred resistance to aminoglycoside kanamycin, a second-line 
antituberculosis drug (Zaunbrecher et al., 2009). More recently, M. 
tuberculosis Eis was demonstrated to have an unprecedented ability to 
acetylate multiple amines of many aminoglycosides and its reaction 
mechanism was proposed on the basis of structural and mutational studies 
(Chen et al., 2011). However, the fundamental question about the 
mechanism of enhanced survival of the M. smegmatis clone, which contains 
the extra M. tuberculosis eis gene in addition to its own eis gene, still 
remains unanswered. Nonpathogenic M. smegmatis contains a homologous 
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eis gene (M. SMEGMATISEG_3513) that encodes a homolog of M. 
tuberculosis Eis (58% amino acid sequence identity). 
M. tuberculosis Eis enhances macrophage survival through the 
regulation of JNK-dependent ROS signaling (Shin et al., 2010), while 
DUSP16/MKP-7 works as a JNK-specific phosphatase in vivo (Masuda et al., 
2001). Acetylation at Lys57 of DUSP1/MKP-1, a phosphatase that 
inactivates MAPK members by dephosphorylation, increased the interaction 
of DUSP1/MKP-1 with its substrate p38 MAPK and inhibited innate 
immune signaling (Cao et al., 2008; Chi and Flavell, 2008).  
On the basis of these reports, I spectulated that M. tuberculosis Eis may 
acetylate component(s) of the MAPK signaling pathways, such as MAPK 
phosphatases, to negatively control autophagy, phagosome maturation, and 
ROS generation, ultimately leading to the suppression of host immune 
responses. 
To better understand how M. tuberculosis Eis enhances mycobacterial 
survival in macrophages, I have carried out functional and structural   
characterization of Eis proteins from both M. tuberculosis and M. smegmatis. 
I find that both Eis proteins can acetylate aminoglycosides efficiently. I have 
discovered that Lys55 within the docking domain (also called the kinase 
interaction motif) of DUSP16/MKP-7 is readily acetylated by M. 
7 
 
tuberculosis Eis, but not by M. smegmatis Eis. Furthermore, I show that M. 
tuberculosis Eis, but not M. smegmatis Eis, inhibits lipopolysaccharide-
induced JNK phosphorylation. The observed functional difference against 
the DUSP16/MKP-7 peptide and JNK can be understood by comparing the 
structures of the two Eis proteins. The overall monomeric and oligomeric 
structures of both M. tuberculosis Eis and M. smegmatis Eis are highly 
similar to each other. The most notable structural difference between them is 
the presence of a narrow channel for potential sequence-specific binding of 
the acetylation target peptide in the active site of M. tuberculosis Eis but not 
in M. smegmatis Eis. On the basis of these findings, I propose that M. 
tuberculosis Eis initiates the inhibition of autophagy and phagosome 
maturation in infected macrophages by N-acetylating Lys55 of 
DUSP16/MKP-7 to suppress host immune responses for intracellular 




Figure 1. Survival of M. smegmatis containing pOLYG (control, shuttle 
vector) or p69 (pOLYG +M. tuberculosis Eis open reading frame) in U-




Figure 2. Sequence alignment of M. tuberculosis and M. smegmatis Eis 
Conserved residues are shaded in green. Cylinders denote α- and 310-helices 
and arrows denote -strands, respectively. The P-loop sequence motif is 
enclosed in a red box. A red triangle above the sequences indicates the 
conserved tyrosine shaded in red (Tyr132 in M. tuberculosis Eis; Tyr126 in 
M. smegmatis). Every 20th residue is marked with a vertical bar and a 
broken bar above the M. tuberculosis Eis sequence and below the M. 
smegmatis Eis sequence, respectively. This figure was drawn with ClustalX 
(Thompson et al., 1997) and GeneDoc(http://www.psc.edu/biomed/genedoc). 
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2. Material and methods 
 
2.1. Protein expression, purification, and mutagenesis 
The Rv2416c gene encoding M. tuberculosis Eis was amplified by the 
polymerase chain reaction using the genomic DNA of M. tuberculosis 
H37Rv as the template. It was inserted into the BamHI/NotI-digested 
expression vector pET-28b(+) (Novagen), resulting in a twenty-residue 
hexahistidine-containing tag at its N-terminus. The recombinant M. 
tuberculosis Eis protein was expressed in E. coli Rosetta II(DE3)pLysS cells 
(Invitrogen). The cells were grown at 37C up to OD600 of ~0.5 in Terrific 
Broth medium that contained 30 g ml-1 kanamycin and the protein 
expression was induced by 0.5 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG). The cells were continued to grow at 18C for 6 h after IPTG 
induction and were harvested by centrifugation at 4,200 g (6,000 rev min-1; 
Sorvall GSA rotor) for 10 min at 4C. The cell pellet was resuspended in an 
ice-cold lysis buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl at 
pH 7.9, 10%(v/v) glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM 
tris(2-carboxyethyl)phosphine (TCEP) and was then homogenized with an 
ultrasonic processor. The crude cell extract was centrifuged at 36,000 g 
(18,000 rev min-1; Hanil Supra 21K rotor) for 60 min at 4C and the 
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recombinant protein in the supernatant fraction was purified in three 
chromatographic steps. The first step was the metal-chelate chromatography 
on Ni-NTA resin (Qiagen). The protein was eluted with a lysis buffer 
containing 500 mM imidazole and the eluted sample was diluted five-fold 
with buffer A (20 mM Tris-HCl at pH 8.5, 0.1 mM TCEP). The diluted 
sample was applied to a Source 15Q ion-exchange column (GE Healthcare), 
which was previously equilibrated with buffer A. The protein was eluted 
with a linear gradient of 01.0 M NaCl in buffer A. The next step was gel 
filtration on a HiLoad 16/60 Superdex-200 prep-grade column (GE 
Healthcare), employing an elution buffer of 20 mM Tris-HCl at pH 8.5, 0.1 
mM TCEP, and 150 mM NaCl. The purified protein was concentrated to 5.0 
mg/ml using Centricon YM-10 (Millipore). 
For overexpressing the selenomethionine (SeMet)-substituted Eis 
protein from M. tuberculosis in E. coli Rosetta(DE3) cells, I used the M9 cell 
culture medium that contained extra amino acids including SeMet. When the 
cell culture reached an OD600 of 0.6, SeMet was added at 50 mg/L and at the 
same time the synthesis of Met was repressed by the addition of Phe, Thr, 
and Lys at 100 mg L-1, and Leu, Ile, Val, and Pro at 50 mg L-1 (20). After 15 
min, expression of the SeMet-substituted protein was induced with 0.4 mM 
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IPTG and the culture was grown for additional 20 h at 20C. The procedure 
for purifying the SeMet-substituted protein was the same except for the 
presence of 10 mM dithiothreitol in all buffers used during purification steps 
besides buffer A. 
The recombinant M. smegmatis Eis with an N-terminal hexahistidine-
containing tag was expressed and purified essentially as above, except the 
following differences. E. coli cells were grown at 37C for 6 h after IPTG 
induction and the concentration of Tris-HCl was 50 mM in the lysis buffer 
and buffer A. The purified M. smegmatis Eis protein was concentrated to 
43.0 mg/ml. 
The gene encoding the human DUSP16/MKP-7 (residues 1153) fused 
with a C-terminal hexahistidine-containg tag was cloned into the NdeI/XhoI-
digested expression vector pET-21a(+) (Novagen). The recombinant protein 
was expressed in E. coli Rosetta II(DE3) cells (Invitrogen) and purified 
essentially as above. The full-length DUSP16/MKP-7 was not expressed in 
E. coli. 
 
2.2. Crystallization and X-ray data collection 
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Crystals M. tuberculosis Eis were grown at 24°C using both the hanging 
drop and sitting drop vapor diffusion methods (Figure 3A). Each hanging or 
sitting drop was prepared by mixing equal volumes (1 l each) of the M. 
tuberculosis Eis protein solution (at 5.0 mg ml-1 concentration in 20 mM 
Tris-HCl at pH 8.5, 0.1 mM TCEP, 150 mM NaCl) and the reservoir 
solution. The reservoir solution was 480 l for the hanging drop experiments 
and 75 l for the sitting drop experiments. P21 crystals of the SeMet-
substituted M. tuberculosis Eis in the acetyl CoA-bound form were grown in 
about two days using a reservoir solution of 12%(w/v) PEG 3350 and 300 
mM ammonium citrate at pH 7.0. Acetyl CoA was not intentionally added to 
the protein solution during the crystallization step, because it caused 
precipitation. Acetyl CoA was apparently picked up by the recombinant 
protein in E. coli and remained bound to the protein throughout purification 
and crystallization steps. H32 crystals of the native M. tuberculosis Eis in the 
apo form were obtained in about two days using the same reservoir solution 
of 12%(w/v) PEG 3350 and 300 mM ammonium citrate at pH 7.0. 
Apparently, the purified protein sample contained both acetyl CoA-bound 
and unbound Eis. 
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P212121 crystals of M. smegmatis Eis were grown at 24°C using sitting 
drop vapor diffusion method (Figure 3B). Each sitting drop was prepared by 
mixing equal volumes (1 l each) of the M. smegmatis Eis protein solution 
(at 43.0 mg ml-1 concentration in 20 mM Tris-HCl at pH 8.5, 0.1 mM TCEP, 
150 mM NaCl) and the reservoir solution. The reservoir solution (75 l) 
contained 100 mM sodium chloride, 100 mM sodium citrate at pH 5.6, and 
12%(w/v) PEG 4000. CoA was not intentionally added during the 
crystallization step but was apparently picked up by the recombinant protein 
in E. coli and remained bound to the protein throughout purification and 
crystallization steps. 
Single-wavelength anomalous diffraction (SAD) data were collected at 
100 K from a crystal of the SeMet-substituted M. tuberculosis Eis protein in 
the acetyl CoA-bound form at the peak wavelength on a Quantum 315 CCD 
detector (Area Detector Systems Corporation, Poway, California) at the BL-
5A experimental station of Photon Factory, Japan. The crystal was flash-
frozen using a cryo-protectant, which was the reservoir solution 
supplemented with 30%(v/v) glycerol. Raw data were processed and scaled 
using the program HKL2000 and SCALEPACK (Otwinowski and Minor,  
1997). The space group was P21, with unit cell parameters of a = 108.13 Å,b 
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= 150.19 Å, c = 184.38 Å, β = 103.05° (Table 1). Assuming two Eis 
hexamers in the asymmetric unit, the Matthews coefficient is 2.55 Å3 Da-1 
and the solvent content of 51.8%.  
The apo crystal of the native M. tuberculosis Eis was flash-frozen using 
a cryo-protectant, which was the reservoir solution supplemented with 
30%(v/v) glycerol. X-ray diffraction data were collected on a Quantum 315 
CCD detector at the BL38B1 experimental station of SPring-8, Japan. The 
space group was H32, with unit cell parameters of a = b = 174.57 Å, c = 
122.83 Å,  =  = 90, and  = 120 (Table 1). The presence of one Eis 
monomer in the asymmetric unit gives the Matthews coefficient of 3.75 Å3 
Da-1 and the solvent content of 67.2%.  
A crystal of M. smegmatis Eis was transferred to a cryoprotectant 
solution which contained 30%(v/v) glycerol in the reservoir solution. X-ray 
diffraction data were collected on a Quantum 315 CCD detector at the BL-
4A experimental station of Pohang Light Source, Korea. The space group 
was P212121, with unit cell parameters of a = 107.74 Å, b = 126.52 Å, c = 
238.80 Å,  =  =  = 90° (Table 1). The presence of one hexamer in the 
asymmetric unit gives the Matthews coefficient of 2.94 Å3 Da-1 and the 
solvent content of 58.2%. 
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2.3. Structure solution and refinement 
Using the SAD data of the SeMet-labeled M. tuberculosis Eis crystal in 
the acetyl CoA-bound form, 72 of the 84 expected selenium atoms in twelve 
Eis monomers were located with the SnB program package (Miller et al., 
1994), except those of the amino terminal methionines. The phases were 
calculated by the program SOLVE (Terwilliger and Berendzen, 1999) and 
were improved through non-crystallographic symmetry averaging, solvent 
flattening, and histogram matching with the program RESOLVE 
(Terwilliger, 2000). An initial model was built manually using the program 
Coot (Emsley and Cowtan, 2004) and the model was refined with the 
program packages CCP4 (Collaborative Computational Project, Number 4, 
1994), CNS (Brünger et al., 1998), and PHENIX (Adams et al., 2010). 
Subsequently, this model was used as a probe to solve the structures of M. 
tuberculosis Eis in the apo form and M. smegmatis Eis (in the CoA-bound 
form) by the molecular replacement method using the program PHASER 
(McCoy et al., 2007). The refined models were evaluated using MolProbity 
(Chen et al., 2010).  
 
2.4. Spectrophotometric acetylation assay of aminoglycosides and 
steady-state kinetic measurements  
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The spectrophotometric assay of acetyltransferase activity was 
performed by coupling the free thiol group of CoA, the reaction product, to 
4,4’-dithiodipyridine to produce thiopyridone, which can be monitored by an 
increase in absorbance at 324 nm (ε324 = 19,800 M
-1cm-1) (Chen et al., 2011; 
Hegde et al., 2001). The reaction was initiated by adding the Eis protein 
solution (final concentration 0.5 μM) to the reaction mixture (total 100 μL) 
containing acetyl CoA (0.1 mM or 1 mM), aminoglycoside (0.1 mM), 4,4’-
dithiodipyridine (2 mM), and Tris-HCl at pH 8.0 (50 mM) at 25°C. 
Reactions were monitored by taking absorbance readings at 1 min interval 
for the first 60 min and at 5 min interval for additional 120 min in a 96-well 
plate format. The kinetic parameters for acetylation of aminoglycosides by 
Eis were determined at 25°C in reaction mixtures (total 100 μL) containing a 
fixed concentration of acetyl CoA (0.1 mM), varied concentrations of 
aminoglycoside (0, 5, 10, 20, 50, 100, 250, 500 μM), 4,4’-dithiodipyridine (2 
mM), Tris-HCl at pH 8.0 (50 mM), and Eis (0.25 μM). Reactions were 
initiated by the addition of acetyl CoA and were carried out in duplicate. Net 
acetylation was monitored by measuring the absorbance at 324 nm as a 
function of time for each concentration of aminoglycoside. The kinetic 
parameters, Km and kcat, were determined from the linear parts of these time 
courses by using Lineweaver-Burk plots. 
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2.5. In vitro acetylation of synthetic peptides and mass spectrometry  
The Eis protein (4 nmol) and the peptide (4 nmol) were incubated at 
37°C for 30 min in a buffer (total 30 μl) containing 50 mM Tris–HCl at pH 
8.0, 10%(v/v) glycerol, 1 mM DTT, 1 mM EDTA, 10 mM sodium butyrate, 
and 1 mM acetyl CoA. As a negative control, I also monitored acetylation in 
the presence of acetyl CoA only. The MALDI-TOF mass spectrometry (MS) 
analysis was done as in (Shin and Kim, 2011). Peptide fragmentation and 
MALDI MS/MS analysis were carried out in the positive ion mode using the 
LIFT-TOF/TOF technique on an Autoflex II MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics). Data were analyzed using Flex Analysis 
2.4 and Bio-Tools 3.0 software (Bruker Daltonics).  
 
2.6. In vitro protein N-acetylation assay  
To assay the protein N-acetyltransferase activity, His-tagged Eis protein 
(400 ng) and human DUSP16/MKP-7 (residues 1153) (500 ng) were 
incubated in the buffer (50 mM Tris-HCl at pH 8.0, 0.1 mM EDTA, 1 mM 
dithiothreitol, 10 mM sodium butyrate, 10%(v/v) glycerol) and 3 l of [14C]-
labeled acetyl CoA (0.05 mCi ml-1, 53 mCi mmol-1) was added in a total 
volume of 30 l. After incubation at 37°C for up to 120 min, the reaction 
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products were analyzed by SDS-PAGE and the protein bands were stained 
by Coomassie brilliant blue. Acetylated proteins were visualized using a 
Bioimage analyzer (BAS-1500, Fuji Film, Japan). 
 
2.7. Cell culture and Western blotting 
Bone marrow-derived macrophages (BMDMs) were isolated and then 
differentiated by growth for 57 days in a medium containing macrophage-
colony stimulating factor (25 μg mL-1; R&D Systems), as described 
previously (Shin et al., 2010). Treated BMDMs were processed for analysis 
by Western blotting as described previously (Shin et al., 2010). For Western 
blot analysis, primary antibodies were diluted 1:1000. Membranes were 
developed using a chemiluminescent reagent (Amersham ECL; GE 
Healthcare) and subsequently exposed to film. Data obtained from 
independent experiments (presented as mean ± SD) were analyzed by the 









Figure 3. Crystals of Eis from M. tuberculosis and M. smegmatis 
(A) Crystals of Eis from M. tuberculosis. They belong to a space group P21. 
Their approximate size is 0.2 mm  0.05 mm  0.05 mm.  
(B) Crystals of Eis from M. smegmatis. They belong to a space group 






Table 1. Data collection, phasing, and refinement statistics 
A. Data collection and phasing statistics 
Protein M. tuberculosis Eis  M. smegmaits Eis 
Data set 
Acetyl CoA  
(SeMet SAD) 
Apo (Native) CoA (Native) 
Resolution range (Å) 30.0–2.80 (2.85–2.80)a 30.0–2.46 (2.55-2.46)a 30.0–2.03 (2.06–2.03)a 
X-ray source Photon Factory BL-5A SPring-8 BL-38B1 PLS BL-4A 
X-ray wavelength (Å) 0.9792 (peak) 1.0000 1.0000 
Space group P21 H32 P212121 
a, b, c (Å) 108.13, 150.19, 184.38 174.57, 174.57, 122.83 107.74, 126.52, 238.80 
, ,  () 90, 103.05, 90 90, 90, 120 90, 90, 90 
Total/unique reflections 977,419 / 269,936b 418,719 / 25,478 1,110,387 / 203,855 
Completeness (%) 97.1 (95.6)a 99.9 (99.1)a 96.3 (96.0)a 
Mean (I/I) 19.3 (3.88)
a 37.2 (5.83)a 36.9 (4.36)a 
Rmerge (%)
c 9.7 (42.7)a 11.2 (48.7)a 6.0 (39.6)a 
f’ / f” (e-) –8.15 / 3.84  
Figure of meritd for SAD phasing (20.0–2.80 Å): 0.50 / 0.72 (before / after density modification) 
B. Refinement statistics    
Resolution range (Å) 30.0–2.80 20.0–2.50 20.0–2.03 
Rwork / Rfree
 (%)e 19.2 / 24.8 18.3 / 21.6 18.1 / 21.7 
No. of residues / mean B-
factor (Å2) 4,752 / 40.1 396 / 32.7 2,412 / 31.7 
No. of waters / mean B-
factor (Å2) 489 / 29.5 137 / 34.1 2,007 / 35.9 
No. of ligands / mean B-
factor (Å2) 12 / 53.5 0 6 / 32.3 
R.m.s.deviation     
Bond lengths (Å)  0.008 0.008 0.007 
Bond angles () 1.23 1.11 1.19 
Ramachandran plot    
Most favorable (%) 95.7 97.7 98.5 
Allowed (%) 4.2 2.3 1.5 




Footnotes for Table 1 
 
a Values in parentheses refer to the highest resolution shell. 
b Values obtained by treating Friedel pairs as separate observations for the SAD 
data. 
c Rmerge = hi | I(h)i – I(h) | / hi I(h)i, where I(h) is the intensity of 
reflection h, h is the sum over all reflections, and i is the sum over i 
measurements of reflection h.  
d Figure of merit =  |  P()ei /  P() | , where  is the phase angle and 
P() is the phase probability distribution. 
e R =  | |Fobs| – |Fcalc| | /  |Fobs|, where Rfree is calculated for a randomly 
chosen 10% of reflections, which were not used for structure refinement, and 




3. Results and discussion 
 
3.1. Overall structure and structural similarity search 
The Eis monomer of both M. tuberculosis and M. smegmatis is tripartite, 
consisting of three “structural” domains (Figure 4). “Structural” domain 1 
(residues 1–142 and 298–305 in M. tuberculosis; residues 1–136 and 290–
297 in M. smegmatis) shows the GNAT fold, as predicted by sequence 
analysis. Unexpectedly, “structural” domain 2 (residues 143–297 in M. 
tuberculosis; residues 137–289 in M. smegmatis) shares the same GNAT 
fold, despite no significant sequence identity with “structural” domain 1 
(6.7% identity in M. tuberculosis; 4.8% in M. smegmatis). “Structural” 
domain 3 (residues 306–408 in M. tuberculosis; residues 298–402 in M. 
smegmatis) resembles the sterol carrier protein-2 (SCP-2) domain, which 
was also not predictable from the amino acid sequence due to no detectable 
sequence identity. 
“Structural” domain 1, folded into the GNAT structure, has a six-
stranded β sheet flanked by two α helices (α1 and α2) on one side, and by 
one α helix (α3) and a 310 helix (α4) on the other side. The central β sheet is 
arranged in the order β1↑-β2↓-β3↑-β4↓-β5↓-β12(C-terminal part)↑. In this 
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domain, the N-terminal β1 strand is “structurally” preceded by the C-
terminal part of β12 strand and is followed by two helices (α1 and α2), three 
antiparallel β strands (β2-β3-β4), a “signature” central helix (α3) (1), a fifth β 
strand (β5), a 310 helix (α4), and a sixth β strand (β12). The N-terminal part 
(residues 291–297 in M. tuberculosis; residues 283–289 in M. smegmatis) of 
the long strand β12 belongs to the central β sheet of “structural” domain 2, 
while its C-terminal portion (residues 298–304 in M. tuberculosis; residues 
290–296 in M. smegmatis) forms part of the central β sheet of “structural” 
domain 1. The long strand β12 serves as a linker between “structural: 
domains 2 and 3. “Structural” domain 1 of M. tuberculosis Eis contains a β 
bulge in strand β4 at Ser89 and Phe90, and an extended P-loop between β4 
and α3 (Figure 5). “Structural” domain 1 of M. smegmatis Eis contains a β 
bulge in strand β4 at Ser83 and Phe84, and an extended P-loop between β4 
and α3. They are conserved features of other GNAT superfamily members 
(Vetting et al., 2005). The β bulge splits the central β sheet into two arms, 
resulting in the V-shaped acetyl CoA binding site between β4 and β5. The P-
loop plays a role in acetyl CoA (or CoA) recognition. 
Unexpectedly, “structural” domain 2 (residues 143–297 in M. 
tuberculosis; residues 137–289 in M. smegmatis) is also folded into the 
GNAT structure. Between “structural” domains 1 and 2, the root-mean-
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square (r.m.s.) deviation is 3.0 Å for 150 C atom pairs in acetyl CoA-bound 
M. tuberculosis and 2.6 Å for 144 C atom pairs in M. smegmatis. 
“Structural” domain 2 contains a seven-stranded β sheet packed on one side 
by a pair of helices (α5 and α6) and on the other side by another pair of 
helices (α7 and α8). The strands of the β sheet are arranged in the order β7↑-
β8↓-β9↑-β10↓-β11↓-β6↑-β12 (N-terminal part)↓. In “structural” domain 2 of 
M. tuberculosis Eis, a β bulge is present at Ser245 and Glu246 in strand β10, 
whereas the P-1oop located between β10 and α7 is highly truncated (Figure 
5). In “structural” domain 2 of M. smegmatis Eis, a β bulge is present at 
Val237 and Glu238 in strand β10, whereas the P-1oop located between β10 
and α7 is highly truncated. Consistent with this observation, acetyl CoA (or 
CoA) is bound to domain 1 only but not to domain 2 in ligand-bound 
structures. Furthermore, a conserved tyrosine residue (Tyr132 in M. 
tuberculosis; Tyr126 in M. smegmatis) in “structural” domain 1, which is 
predicted to be important for the acetyltransferase activity (Vetting et al., 
2005), is replaced by a leucine residue (Leu281 in M. tuberculosis; Leu272 
in M. smegmatis) in “structural” domain 2 (Figure 2). This suggests that only 
“structural” domain 1 is catalytically active and “structural” domain 2 may 
serve a different noncatalytic function such as substrate binding.  
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“Structural” domain 3 (residues 306–408 in M. tuberculosis; residues 
298–402 in M. smegmatis) contains a five-stranded β sheet in the order 
β15↓-β14↑-β13↓-β16↓-β17↑ (Figure 4). One face of the β-sheet is covered 
by four α helices (α9, α10, α11, and α12), whereas the other side is not 
covered by α helices (Figure 4). It is structurally related to SCP-2 domains 
(Stolowich et al., 2002). SCP-2, also called nonspecific lipid transfer protein, 
is a nonspecific lipid-binding protein expressed ubiquitously in most 
organisms. In vertebrates, SCP-2 serves not only in cholesterol and 
phospholipid transfer, but also in regulating multiple lipid signaling 
pathways in lipid raft/caveolae microdomains of the plasma membrane 
(Stolowich et al., 2002). In insects, SCP-2 is involved in cholesterol uptake 
in the midgut in both larval and adult mosquito (Singarapu et al., 2010). 
Structures of human and mosquito SCP-2 have been reported, both in the 
apo form and in the ligand-bound forms (Singarapu et al., 2010; García et al., 
2000; Haapalainen et al., 2001; Haapalainen et al., 2001). Crystal structures 
of the putative SCP-2 (TT1886) from Thermus thermophilus HB8 have been 
determined in both open and closed conformations (Goroncy et al., 2010). 
The most prominent structural feature of SCP-2 proteins is the presence of a 
hydrophobic cavity for lipid binding (Stolowich et al., 2002). Cavity 
volumes are 1,100 Å3 for human SCP-2 (PDB 1IKT), 750 Å3 for mosquito 
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SCP-2 (PDB 1PZ4), and 470/570 Å3 for T. thermophilus HB8 SCP-2 like 
protein in the open/closed conformations (PDB 2CX7 chain A/B) (Dundas et 
al., 2006). “Structural” domain 3 of M. tuberculosis Eis has a much smaller 
cavity volume of 250 and 240 Å3 for acetyl CoA-bound and apo structure of 
M. tuberculosis Eis, whereas that of CoA-bound M. smegmatis Eis has no 
detectable cavity. 
A structural similarity search with M. tuberculosis Eis monomer (chain 
A in the acetyl CoA-bound structure) using the program DALI (Holm and 
Rosenström, 2010) reveals that members of the GNAT superfamily give the 
highest Z-scores. Excluding Eis, they are (i) GNAT family acetyltransferase 
from A. variabilis ATCC 29413 (PDB code 2OZG, Z score = 39.6, r.m.s. Cα 
deviation = 2.5 Å, sequence identity = 22% for 371 residues), (ii) GNAT 
family acetyltransferase from E. faecalis (PDB code 2I00, Z score = 37.9, 
r.m.s. Cα deviation = 2.4 Å, sequence identity = 17% for 364 residues), (iii) 
a hypothetical protein from E. faecalis V583 (PDB code 2HV2, Z score = 
37.0, r.m.s. Cα deviation = 2.7 Å, and a sequence identity = 19% for 369 
residues), and (iv) GNAT family acetyltransferase from Bacillus anthracis 
(PDB code 3N7Z, Z score = 36.4, r.m.s. Cα deviation = 2.4 Å, sequence 
identity = 17% for 362 residues). When I further elaborated the structural 
similarity search using each of “structural” domain 1, 2, or 3, the results 
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were similar to that obtained using the whole monomer. However, these 
proteins have not been well characterized functionally. 
Below the above four best matches, better characterized proteins that 
structurally resemble M. tuberculosis Eis are as follows. For “structural” 
domain 1 (chain A, acetyl CoA-bound model), the GNAT domains of M. 
tuberculosis aminoglycoside 2’-N-acetyltransferase (AAC; PDB ID 1M4G) 
(Vetting et al., 2002), Ovis aries serotonin N-acetyltransferase (PDB ID code 
1L0C) (Scheibner et al., 2002), human p300/CBP-associating factor (PCAF; 
PDB ID 1CM0) (Clements et al., 1999), and Salmonella typhimurium N-
acetyltransferase RimL (PDB ID code 1S7L) (Vetting et al., 2005) show 
r.m.s. differences of 1.8, 1.8, 2.0, and 2.8 Å for 143 C atom pairs, 
respectively. For “structural” domain 2, the GNAT domains of AAC, 
serotonin N-acetyltransferase, PCAF, and RimL show r.m.s. differences of 
2.9, 2.5, 2.8, and 3.1 Å for 150 C atom pairs, respectively. This result 
indicates that “structural” domain 2 of M. tuberculosis Eis is structurally 
more divergent from these GNAT enzymes than “structural” domain 1. For 
“structural” domain 3, SCP-2 proteins are structurally similar. For example, 
between “structural” domain 3 and the mosquito SCP-2 (PDB code 1PZ4) 
(Dyer et al., 2003), the r.m.s. deviation is 2.6 Å for 84 equivalent Cα 
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positions (residues 306–408 of M. tuberculosis Eis), with a Z-score of 8.1, 
and a sequence identity of 17%. 
Interestingly, a putative peroxisome targeting signal type 2 (PTS2) is 
present in “structural” domain 3 of M. tuberculosis Eis as 
380RLRTKDSQL388 (Figure 2). The generally accepted PTS2 sequence is 
(R/K)-(L/V/I)-xxxxx-(H/Q)-(L/A) (Lazarow, 2006). The crystal structures of 
two PTS2s in fructose-1,6-bisphosphate aldolases from Trypanosoma brucei 
and Leishmania mexicana are virtually identical (Lazarow, 2006). Nine C 
atoms of the putative PTS2 sequence in “structural” domain 3 of M. 
tuberculosis Eis (chain A, acetyl CoA-bound model) overlap with the T. 
brucei (or L. mexicana) PTS2 with an r.m.s. deviation of 2.4 Å. The highly 
conserved four residues are all located on the surface, thus allowing them to 
possibly interact with the import receptor Pex7p. If the putative PTS2 in 
“structural” domain 3 of M. tuberculosis Eis is functional, Eis may be 
translocated into the peroxisomal matrix to disturb the normal peroxisome 
function and may influence the production of hydrogen peroxide, which acts 
as a cell-survival signaling molecule (Groeger et al., 2009). It is also 
interesting to note that a conserved residue (His or Gln) at position no. 8 is 
replaced by Glu in the corresponding sequence (RLRSKDSEL) of M. 
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smegmatis Eis domain 3. Basic amino acids were not tolerated at position no. 
8 (Lazarow, 2006). Replacement of Gln by Glu at position no. 8 in the 
PTS2-like sequence of M. tuberculosis Eis alters the surface charge property 
(Figure 6). All the known functional PTS2s are located at or near the amino 
terminus (Lazarow, 2006). Even though the PTS2-like sequence of M. 
tuberculosis Eis is located near the carboxyl terminus, further experimental 
testing of potential new PTS2s is required to determine whether they are 
functional or not (Lazarow, 2006). It is worth noting that human and 
mosquito SCP-2 proteins contain a PTS1 sequence (A/S-K-L) at the 
carboxyl terminus (Lensink et al., 2002), while T. thermophilus HB8 SCP-2 
like protein contains neither a PTS1-like sequence nor a PTS2-like sequence 




Figure 4. Structures of M. tuberculosis and M. smegmatis Eis 
(A) Cartoon representation of the M. tuberculosis Eis monomeric structure. 
Helices and strands are colored in light blue and lime, respectively. Acetyl 
CoA is drawn in an orange stick model. (B) Topology diagram of M. 
tuberculosis Eis with helices and strands represented with circles (in blue) and 
triangles (in lime), respectively. (C) Cartoon representation of the M. 
smegmatis Eis monomeric structure. Helices and strands are colored in 
purple and orange, respectively. CoA is drawn in a cyan stick model. (D) 
Topology diagram of M. smegmatis Eis with helices and strands represented with 




Figure 5. Sequence alignment and structural superposition of domains 1 
and 2 of M. tuberculosis Eis 
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(A) Sequence alignment of M. tuberculosis Eis “structural” domains 1 and 2. 
Conserved residues are shaded in green. Cylinders above and below the 
sequences denote helices and arrows -strands. Dotted lines represent 
disordered residues. A red triangle above the sequences indicates Tyr132. 
The P-loop sequence motif is enclosed in a red box. The N- and C-terminal 
portions of the long strand β12 are located at the edge of the β-sheets in 
domains 2 and 1, respectively. (B) Stereo view of the superposition of 
“structural” domains 1 and 2 in M. tuberculosis Eis. “Structural” domains 1 
and 2 are colored in ruby and light blue, respectively. Acetyl CoA bound to 
domain 1 is shown in a stick model. A red box indicates the loop between 
β4-α3 in “structural” domain 1 and the highly truncated loop between β10-
α7 in “structural” domain 2. The P-loops are located in the bottom region of 
this red box. (C) Close-up, stereo view of acetyl CoA binding to “structural” 
domain 1. β4/α3/β5/α4 in “structural” domain 1 and β10/α7/β11/α8 in 
“structural” domain 2 are indicated. A red box indicates the loop between 
β4-α3 in “structural” domain 1 and the highly truncated loop between β10-
α7 in “structural” domain 2. The P-loops are located in the bottom region of 
this red box. The side chains of Tyr132 in “structural” domain 1 and Leu281 




Figure 6. PTS2 region in Eis domain 3 
(A) Electrostatic potential at the surface of the PTS2 region in M. 
tuberculosis Eis “structural” domain 3. Blue and red colors correspond to 
positive and negative potentials, respectively. (B) Electrostatic potential at 
the surface of the PTS2 region in M. smegmatis Eis “structural” domain 3. 
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3.2. Quaternary structure of Eis proteins 
In all three Eis structures, six monomers are assembled into a 
homohexamer with point group symmetry 32 (Figure 7). The hexameric 
association leads to the burial of a total of 27,100, 27,200, and 26,700 Å2 of 
the solvent-accessible surface area per hexamer for the acetyl CoA-bound 
and apo structures of M. tuberculosis Eis and for CoA-bound M. smegmatis 
Eis, respectively. Extensive interactions across the inter-subunit interfaces in 
the Eis hexamer suggest that the hexameric structure of Eis observed in the 
crystal is likely to exist in solution and is biologically relevant. 
A hexamer of Eis can be described as a trimer of dimers. The dimer 
interface buries 5,000, 5,100, and 5,040 Å2 per monomer of solvent-
accessible surface area in the acetyl CoA-bound and apo structures of M. 
tuberculosis Eis and for CoA-bound M. smegmatis Eis, respectively. 
“Structural” domains 2 and 3 are primarily involved in the dimer interface. 
In the M. tuberculosis Eis structure, this interface is mainly contributed by 
residues Gln278–Asp298 from helix α8, strand β12, and the following loop 
of “structural” domain 2, and by residues Arg371–Arg390 from helices α11 
and α12 of “structural” domain 3. When I view the hexamer along its three-
fold axis, two triangles representing the two layers of a trimeric unit make a 
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30 angle. “Structural” domains 1 and 2 alternate within a trimeric unit, 
whereas “structural” domain 3 is located at the periphery of the triangular-
shaped trimeric unit. “Structural” domain 2 is located closer to the interface 
between two layers of the trimeric unit and two such “structural” domains 
from different layers make extensive contacts with each other, whereas 
“structural” domain 1 plays an insignificant role in the contact between the 
two layers of the trimeric unit. Interestingly, one side of the -sheet in 
“structural” domain 3 that is not covered by helices is exposed to the bulk 




Figure 7. Hexameric arrangement of Eis proteins 
(A) Cartoon representation of the M. tuberculosis Eis hexameric structure. 
Two orthogonal views differing by 90 are shown. Individual monomers in 
the hexamer are colored in gray, green, magenta, pink, cyan, and yellow. (B) 
Cartoon representation of the M. smegmatis Eis hexameric structure. Two 
orthogonal views differing by 90 are shown. Individual monomers in the 
hexamer are colored in light blue, teal, blue, light orange, lime, and brown. 
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3.3. Ligand binding at the active site  
The ligand (acetyl CoA or CoA) is bound to “structural” domain 1 but 
not to “structural” domain 2 in both M. tuberculosis and M. smegmatis Eis 
structures, despite sharing the common GNAT fold. The protein-ligand 
interactions in both Eis structures are highly similar to each other and are 
also similar to those that have been observed in a number of other GNAT 
family members. Acetyl CoA (or CoA) is bound between the splayed strands 
β4 and β5 of “structural” domain 1. The P-loop between the strand β4 and 
helix 3 coordinates the pyrophosphate group of acetyl CoA (or CoA) 
(Vetting et al., 2005). The sequences Arg98-Arg99-Arg100-Gly101-Leu102-
Leu103 in M. tuberculosis Eis and Arg92-Arg93-Arg94-Gly95-Val96-Leu97 
in M. smegmatis Eis nearly conform to the P-loop motif [(R/Q)-X-X-G-X-
(G/A)] for acetyl CoA recognition (Neuwald and Landsman, 1997; Shi et al., 
2008). The P-loop is one of the conserved sequence motifs and a conserved 
structural feature of the GNAT superfamily (Vetting et al., 2005). However, 
the P-loop in “structural” domain 2 is highly truncated compared to that in 
“structural” domain 1 (Figure 5), and it explains why acetyl CoA (or CoA) is 
bound to “structural” domain 1 only.  
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In the ligand-bound structure of M. tuberculosis Eis, acetyl CoA makes 
hydrophobic interactions with Phe30, Gly130, and Ile131 in “structural” 
domain 1 (Figure 8). The adenine ring makes a hydrogen bond to the side 
chain of Glu128, while the 3’-phosphoryl group interacts with the side chain 
of Arg134. The pyrophosphate moiety of acetyl CoA makes hydrogen bonds 
to the side chain of Arg99 and the backbone nitrogen atoms of Gly101, 
Leu103, and Arg104. The β-mercaptoethylamine unit makes hydrogen bonds 
with the backbone nitrogen of Val93 and the side chain of Ser127. The 
acetyl carbonyl oxygen atom is hydrogen-bonded to the backbone nitrogen 
atom of Phe90, positioning it for a nucleophilic attack by the substrate amine 
group. The interactions between CoA and M. smegmatis Eis are identical. 
That is, CoA makes hydrophobic interactions with Phe26, Gly124, and 
Ile125 in “structural” domain 1 (Figure 8). The adenine ring makes a 
hydrogen bond to the side chain of Glu122, while the 3’-phosphoryl group 
interacts with the side chain of Arg128. The pyrophosphate moiety of acetyl 
CoA makes hydrogen bonds to the side chain of Arg93 and the backbone 
nitrogen atoms of Gly95, Leu97, and Arg98. The β-mercaptoethylamine unit 
makes hydrogen bonds with the backbone nitrogen of Val87 and the side 




Figure 8. Structural comparison of M. tuberculosis Eis and M. smegmatis 
Eis  
(A) Cartoon representation of ligand binding pocket in M. tuberculosis Eis. (B) 
Cartoon representation of ligand binding pocket in M. smegmatis Eis.. Amino acid 
residues around acetyl CoA or CoA are shown in a stick model. Nitrogen 
and oxygen atoms are colored in blue and red, respectively. Black dotted 
lines denote hydrogen bonds.  
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3.4. Comparison of aminoglycosides acetyltransferase activity of Eis 
Proteins from M. tuberculosis and M. smegmatis 
Recently, M. tuberculosis Eis was shown to acetylate multiple amines of 
many aminoglycosides, including the second line-injectable antituberculosis 
drugs kanamycin and amikacin (Zaunbrecher et al., 2009; Chen et al., 2011). 
It was also argued that kanamycin may not be a natural substrate of M. 
tuberculosis Eis because of a high Km value with it (Zaunbrecher et al., 
2009). To examine whether there is a functional difference between Eis 
proteins from M. tuberculosis and M. smegmatis in aminoglycoside 
acetylation, I have compared acetylation activities of these two Eis proteins 
against amikacin, kanamycin A, tobramycin, and paromomycin. 
Interestingly, M. smegmatis Eis acetylated the tested aminoglycosides as 
quickly as, or more rapidly than, M. tuberculosis Eis (Figure 9). Steady-state 
kinetic parameters, as measured by Km and kcat values (Table 2), indicate that 
the aminoglycoside acetyltransferase activity of M. smegmatis Eis is 
comparable to or higher than that of M. tuberculosis Eis. This result cannot 





Figure 9. Acetylation assay of aminoglycosides by Eis 
(A) Amikacin, (B) kanamycin A, (C) tobramycin, and (D) paromomycin. 
Acetylation of aminoglycosides by Eis was monitored 
spectrophotometrically by measuring the absorbance at 324 nm. Black open 
and closed circles denote the measurements by M. tuberculosis Eis using 10 
and one equivalent(s) of acetyl CoA, respectively. Brown open and closed 
circles denote the measurements by M. smegmatis Eis using 10 and one 
equivalent(s) of acetyl CoA, respectively. 
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Table 2. Kinetic parameters of aminoglycoside N-acetylation by Eis proteins 
 














Amikacin 73 0.017 233 61 0.025 409 
Kanamycin A 81 0.032 395 52 0.041 788 
Tobramycin 71 0.179 2,521 69 0.182 2,638 
Paramomycin 85 0.032 376 48 0.063 1,313 
45 
 
3.5. Comparison of overall structure of Eis proteins from M. tuberculosis 
and M. smegmatis 
To understand the observed catalytic properties, I have determined and 
compared the crystal structures of both M. tuberculosis and M. smegmatis 
Eis proteins. The crystal structure of selenomethionine-substituted M. 
tuberculosis Eis in the acetyl CoA-bound form was determined by de novo 
phasing using the single anomalous diffraction data to 2.80 Å. This model 
was used to solve the structures of M. tuberculosis Eis in the apo form at 
2.46 Å and M. smegmatis Eis in the CoA-bound form at 2.03 Å by molecular 
replacement. The overall monomeric and hexameric structures of M. 
tuberculosis and M. smegmatis Eis proteins are similar to each other (Figure 
4, Figure 7). That is, each monomer of both Eis proteins comprises three 
“structural” domains and six subunits are associated to form a hexamer of 32 
symmetry. “Structural” domain 1 adopts the GNAT fold, as predicted. 
Unexpectedly, “structural” domain 2 is also folded into the GNAT structure 
despite an apparent lack of sequence similarity to other GNAT enzymes, 
including the Eis domain 1. “Structural” domain 3 resembles sterol carrier 
protein-2 (SCP-2). Either acetyl coenzyme A (CoA) or CoA is observed to 
be bound to “structural” domain 1 only, but not to “structural” domain 2, in 
the ligand-bound structures of both Eis proteins (Figure 4). The active sites 
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of M. tuberculosis and M. smegmatis Eis proteins are large and deep enough 
to accommodate aminoglycosides. However, they display distinct structural 
features that may explain the observed functional difference against peptide 
substrates.  
 
3.6. Identification of DUSP16/MKP-7 as the N-acetylation target of M. 
tuberculosis Eis 
Besides aminoglycosides, M. tuberculosis Eis was previously shown to 
acetylate free histone proteins, but not the histone proteins in a nucleosomal 
complex (Crossman, 2007). None of these acetylation targets can explain the 
enhanced intracellular survival of mycobacteria by M. tuberculosis Eis; M. 
tuberculosis Eis likely has other unidentified protein targets for acetylation. 
Therefore, I was interested in identifying physiologically more important 
protein acetylation targets of M. tuberculosis Eis. M. tuberculosis Eis 
enhances macrophage survival through the regulation of JNK-dependent 
ROS signaling (Shin et al., 2010), while DUSP16/MKP-7 works as a JNK-
specific phosphatase in vivo (Masuda et al., 2001). Acetylation at Lys57 of 
DUSP1/MKP-1, a nuclear-localized phosphatase that inactivates MAPK 
members by dephosphorylation, promoted the interaction of DUSP1/MKP-1 
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with its substrate p38 MAPK and inhibited innate immune signaling (Cao et 
al., 2008; Chi and Flavell, 2008). Three major subfamilies of MAPKs are 
ERKs, p38 MAPKs, and JNKs. These MAPKs are activated by MAPK 
kinases, which are in turn activated by a set of MAPK kinase kinases. The 
MAPK pathways that mediate innate immune signaling include MAPK 
kinases 3/4/6, p38, and JNKs (Hegde et al., 2001; and references therein). 
On the basis of these reports, I spectulated that M. tuberculosis Eis may 
acetylate component(s) of the MAPK signaling pathways, such as MAPK 
phosphatases, to negatively control autophagy, phagosome maturation, and 
ROS generation, ultimately leading to the suppression of host immune 
responses. Therefore, I examined whether M. tuberculosis Eis may acetylate 
DUSP16/MKP-7, which is known to be a JNK-specific phosphatase 
(Masuda et al., 2001). I tested a peptide within the MAPK-docking domain 
of DUSP16/MKP-7: 53LMKRRLQQDKVLIT66 [MKP-7(5366)] (Cao et al., 
2008). The underlined Lys62 was predicted to be the acetylation site in the 
DUSP16/MKP-7 docking domain (Cao et al., 2008). I also tested a peptide 
within the MAPK-docking domain of DUSP1/MKP-1: 
50TIVRRRAKGAMGLE63 [MKP-1(5063)] (Cao et al., 2008). The 
underlined lysine was established as the acetylation site in the DUSP1/MKP-
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1 docking domain (Cao et al., 2008). With these peptides as possible 
substrates, I performed in vitro acetylation assays using either M. 
tuberculosis Eis or M. smegmatis Eis. 
The MALDI-TOF mass spectra of the MKP-7(5366) peptide show that 
the unmodified peptide peak at 1,741 Da is shifted to 1,783 Da after in vitro 
acetylation for 5 min by M. tuberculosis Eis (Figure 10). The observed 
increase of 42 Da in the peptide mass corresponds to covalent attachment of 
an acetyl group (CH3CO–). On the other hand, the mass (1,557 Da) of the 
MKP-1(5063) peptide before and after in vitro acetylation for 30 min by M. 
tuberculosis Eis is identical to the predicted mass of the unmodified peptide 
(Figure 10). These results indicate that M. tuberculosis Eis quickly attaches a 
single acetyl group to the MKP-7(5366) peptide, whereas it does not 
readily acetylate the MKP-1(5063) peptide. The MKP-7(5366) peptide 
has three potential N-acetylation sites: one N-acetylation site at the amino 
terminus and two N-acetylation sites at Lys55 and Lys62. In order to 
identify which of the three possible acetylation sites was actually modified, I 
performed de novo sequencing of the acetylated MKP-7(5366) peptide by 
MALDI tandem mass spectrometry (Figure 10). Peaks of unacetylated a1, a2, 
y10, and y11 ions are present at 86.009, 217.157, 1214.653, and 1369.811 
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Da, respectively, while peaks of acetylated b-ion series b3*, b4*, b5*, and 
b8* are present at 415.398, 571.565, 727.680, and 1096.718 Da, respectively. 
This result identifies Lys55 of the MKP-7(5366) peptide as the N-
acetylation site. By analogy with DUSP1/MKP-1 (Cao et al., 2008), I 
suggest that N-acetylation of DUSP16/MKP-7 at Lys55 by M. tuberculosis 
Eis may increase the interactions between DUSP16/MKP-7 and JNK by 
neutralizing the positive charge within the docking domain of 
DUSP16/MKP-7. M. smegmatis Eis acetylated both MKP-1(5063) and 
MKP-7(5366) peptides very quickly in about 5 min, resulting in a mass 
increase by 42 Da. (Figure 10). I have confirmed by MALDI tandem mass 
spectrometry that these peptides are N-acetylated at the amino terminus by 
M. smegmatis Eis (Figure 11). My data thus establish that Eis proteins from 
both M. tuberculosis and M. smegmatis are catalytically active as 
aminoglycoside N-acetyltransferases but only M. tuberculosis Eis acts as an 
efficient N-acetyltransferase that can acetylate DUSP16/MKP-7. 
I further tested the protein N-acetyltransferase activity using the 
recombinant human DUSP16/MKP-7. I could express and purify 
DUSP/MKP-7(1153), which encompasses the docking domain, whereas the 
full-length DUSP16/MKP-7 was not expressed in E. coli. When 
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DUSP16/MKP-7(1153) was incubated with the wild-type M. tuberculosis 
Eis in the presence of [14C]-acetyl CoA, it was efficiently acetylated by M. 
tuberculosis Eis (Figure 12). However, acetylation of DUSP16/MKP-
7(1153) by M. smegmatis Eis was much less efficient (Figure 12). I next 
performed mutation experiments to confirm the acetylation site(s) in 
DUSP16/MKP-7(1153). Each of Lys52, Lys55, and Lys62 in 
DUSP16/MKP-7(1153) was replaced by arginine and the acetylation 
reaction was carried out. Mutation of Lys55 drastically reduced the level of 
acetylation by M. tuberculosis Eis, whereas mutations of Lys52 and Lys62 
showed no such drastic reduction (Figure 12). With M. smegmatis Eis, 
mutation of Lys55 had little effect on the level of acetylation, suggesting that 
acetylation by M. smegmatis Eis likely occurred at the amino terminus, but 
not at Lys55 (Figure 12). These results strongly suggest that M. tuberculosis 




Figure 10. Mass analyses of MKP-7(5366) and MKP-1(5063) peptides 
(A) Mass spectra of MKP-7(5366) and MKP-1(5063) peptides before (top 
panel) and after acetylation by M. tuberculosis Eis (middle) and M. 
smegmatis Eis (bottom). (B) MALDI MS/MS spectrum of the MKP-
7(5366) peptide acetylated by M. tuberculosis Eis. The fragments marked 
with an asterisk (*) are +42 Da-shifted ions, as compared to the counterparts 
that would be generated from the unmodified peptide. The acetylated MKP-
7(5366) fragmentation notation using the scheme of Roepstorff and 
Fohlman is given above the spectrum (Roepstorff and Fohlman, 1984). The 




Figure 11. MALDI MS/MS spectra of the peptides acetylated by M. 
smegmatis Eis  
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(A) MKP-1(5063) peptide and (B) MKP-7(5366) peptide. The fragments 
marked with an asterisk (*) are +42 Da-shifted ions, as compared to the 
counterparts that would be generated from the unmodified peptide. The 
fragmentation notation using the scheme of Roepstorff and Fohlman is given 
above each spectrum (Roepstorff and Fohlman, 1984). The acetyl group 




Figure 12. Acetyltransferase activity assay of M. tuberculosis Eis and M. 
smegmatis Eis using the wild-type and mutants of recombinant human 
DUSP/MKP-7(1153) as potential substrates  
(A) Time-course acetyltransferase activity assay of M. tuberculosis Eis and a 
comparison of M. tuberculosis Eis and M. smegmatis Eis activities. The 
wild-type DUSP16/MKP-7(1153) was incubated with [14C]-labeled acetyl 
CoA and Eis for the indicated duration at 37C. The reaction products were 
separated by 15%(w/v) SDS-PAGE and the acetylated protein bands were 
visualized using a Bioimage analyzer. (B) Acetyltransferase activity of M. 
tuberculosis Eis and M. smegmatis Eis toward the wild-type and mutants of 
DUSP16/MKP-7(1153). All reactions were carried out at 37C for 30 min. 
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3.7. Comparison of substrate binding sites in Eis proteins 
Biochemical studies indicated that both M. tuberculosis and M. 
smegmatis Eis proteins could readily acetylate aminoglycosides, with M. 
smegmatis Eis being a marginally better catalyst as an aminoglycoside N-
acetyltransferase (Figure 9). In contrast, their substrate preferences against 
MKP-7(5366) and MKP-1(5063) peptides were different. M. tuberculosis 
Eis acetylated an internal lysine (Lys55) of the MKP-7(5366) peptide 
rapidly, whereas M. smegmatis Eis preferentially acetylated the terminal 
amino group of these peptides (Figure 10, Figure 11). To understand the 
observed difference in peptide acetylation site preferences, I have compared 
the active site features of these Eis proteins. Both Eis active sites show 
negative electrostatic potential surfaces (Figure 13) and key residues around 
the thiol group of acetyl CoA (or CoA) are identical (Asp32/Tyr132/Phe408 
in M. tuberculosis; Asp28/Tyr126/Phe402 in M. smegmatis). Interestingly, I 
noticed a difference in the shape of the predicted substrate binding sites 
adjacent to the bound ligand in their active sites. M. tuberculosis Eis has a 
deep and narrow channel, whereas M. smegmatis Eis has a deep and round 
pocket (Figure 13). This structural difference in the substrate binding sites is 
mainly due to different arrangements of helix α2 (Gly35–Leu45 in M. 
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tuberculosis Eis; Glu32–Met41 in M. smegmatis), part of “structural” 
domain 1, and helix α6 (Gln200–Cys210 in M. tuberculosis Eis; Asp190–
Ala198 in M. smegmatis) and the following loop, which are part of 
“structural” domain 2 (Figure 14). The narrow channel of M. tuberculosis 
Eis is formed by limited hydrophobic interactions between these helices. In 
comparison, the round pocket-shaped substrate binding site of M. smegmatis 
Eis is formed by extensive interactions between helix α2 in “structural” 
domain 1 and helix α6 followed by an additional 310 helix α6’ in “structural” 
domain 2 (Figure 4). The 310 helix α6’ is present in M. smegmatis Eis only 
(Figure 4). The close contact between α2 and α6 helices in M. smegmatis Eis 
is stabilized by hydrogen bondings of Gln33-Arg200 and Thr34-Asp195 
pairs (Figure 14). In addition, the side chain of Trp42 in M. tuberculosis Eis 
is located between the side chains of Trp19 (on α1) and Phe90 (on β4) in 
“structural” domain 1, while the corresponding residue in M. smegmatis Eis, 
Trp38, is located on the other side of Phe84 and makes van der Waals 
contacts with the side chains of Met41 (on α2), Leu192 (on α6), and Tyr400 
(Figure 14). The elongated substrate-binding channel in M. tuberculosis Eis 
appears to be suitable not only for accommodating aminoglycosides but also 
for recognizing the polypeptide substrate in a sequence-specific manner. The 
deep, round-shaped substrate-binding pocket in M. smegmatis Eis appears 
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more suitable for accommodating aminoglycosides and the terminal amino 




Figure 13. Structures of M. tuberculosis and M. smegmatis Eis  
(A) Electrostatic potential at the surface of M. tuberculosis Eis monomer, 
with an enlarged view from an orthogonal angle. (B) Electrostatic potential 
at the surface of M. smegmatis Eis monomer, with an enlarged view from an 
orthogonal angle. Blue and red colors correspond to positive and negative 
potentials, respectively. Red circles indicate possible substrate binding sites 




Figure 14. Structural comparison of substrate binding site in M. 
tuberculosis Eis and M. smegmatis Eis 
(A) Residues around the substrate binding sites of M. tuberculosis Eis (B) 
Residues around the substrate binding sites of M. smegmatis Eis. These 
close-up views roughly correspond to the regions indicated by red circles in 
Figure 13. Side chains of amino acid residues around the substrate binding 
sites are shown in a stick model. Nitrogen and oxygen atoms are colored in 
blue and red, respectively. Black dotted lines denote hydrogen bonds. All 
figures are drawn in the same view. 
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3.8. M. tuberculosis Eis, but not M. smegmatis Eis, inhibits 
lipopolysaccharide-induced JNK phosphorylation.  
As DUSP16/MKP-7 can dephosphorylate JNK in macrophages in 
response to lipopolysaccharide (LPS) (Tanoue et al., 2001; Han et al., 2002; 
Matsuguchi et al., 2001; Weston and Davis, 2007; Kondoh and Nishida, 
2007), I examined whether M. tuberculosis Eis or M. smegmatis Eis inhibits 
LPS-induced JNK activation in bone marrow-derived macrophages 
(BMDMs). M. tuberculosis Eis significantly reduced the level of 
phosphorylated JNK in BMDMs in response to LPS, whereas M. smegmatis 
Eis did not (Figure 15). These data, together with previous finding that M. 
tuberculosis Eis acetylates DUSP16/MKP-7 at Lys55, indicate that M. 
tuberculosis Eis suppresses host innate immune responses through 





Figure 15. M. tuberculosis Eis, but not M. smegmatis Eis, significantly 
inhibits JNK activation in BMDM cells 
Cells were treated with or without M. tuberculosis Eis (or M. smegmatis Eis) 
(5, 10, or 20 ug ml-1) for 1 h, followed by stimulation with LPS (100 ng ml-1) 
for 30 min. Cells were then harvested, lysed, and subjected to Western blot 
analysis using antibodies raised to phospho-JNK and β-actin. Data shown are 
representative of three independent experiments that all yielded similar 
results. (A) Expression of phospho-JNK and β-actin in cytoplasmic extracts 
of BMDMs was quantified densitometrically (B). Data represent the mean ± 
standard deviation and are representative of three independent experiments. 
***p < 0.001, vs. LPS-stimulated condition; U, untreated; L, LPS-treated 
condition without M. tuberculosis Eis or M. smegmatis Eis. 
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3.9. Mechanism of acetylation by M. tuberculosis Eis  
The ternary Tetrahymena Gcn5 (tGcn5)/CoA/histone H3 complex 
allows one to derive a detailed mechanism of catalysis that is mediated by 
the glutamate within the core domain of Gcn5 (Rojas et al., 2009). Glu407 of 
M. tuberculosis Eis is bound to a water molecule located between the 
Glu407 side chain and the reactive Lys55 residue of the DUSP16/MKP-7. 
This water molecule is ideally located to shuttle a proton from the reactive 
Lys55 of the histone to Glu407 of the protein. The lysine amino group to be 
acetylated is ideally positioned by the His125 backbone for a nucleophilic 
attack on the CoA thioester. The main chain amide nitrogens of Phe 90 and 
Val 91 donate a hydrogen bond to the carbonyl oxygen of the thioester in 
this model, thus polarizing the thioester carbonyl and statbilizing the 
tetrahedral transtion state (Chen et al., 2011). The C-terminal carboxylate of 
Phe408 interacts with the amino group through a bridging water molecule 
and likely serves as a remote base. The conserved Tyr132 at a distance of 3.6 
Å from the sulfhydryl group of CoA likely serves as a general acid to 
protonate the CoA thiolate (Figure 16) (Chen et al., 2011). 
3.10. Mechanism of host immune suppression by M. tuberculosis Eis  
Survival of M. tuberculosis inside human macrophages is central to 
tuberculosis infection, latency, disease activation, and transmission (Russell, 
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2001). The most important survival strategies of the pathogen are the 
inhibition of phagosomal maturation and autophagy (Gutierrez et al., 2004). 
Autophagy has been recognized as innate and adaptive immune defense 
mechanisms (Gutierrez et al., 2004). A functional overlap was suggested 
between phagosome maturation and autophagy, both of which depend on 
Beclin 1 and VPS34 as key players (Gutierrez et al., 2004). Beclin 1, a pro-
autophagy BH3 domain-containing protein, plays a central role in 
autophagosome formation by interacting with several other factors to 
promote the formation of Beclin 1-VPS34-VPS15 core complexes (Kang et 
al., 2011; Funderburk et al., 2010). In mammalian cells under nonstarvation 
conditions, the anti-apoptotic protein Bcl-2 binds to Beclin 1 and inhibits its 
autophagy function (Wei et al., 2008). Starvation induces Bcl-2 dissociation 
from Beclin 1, via phosphorylation of Bcl-2, and autophagy activation. 
Furthermore, JNK1, but not JNK2, was found to mediate starvation-induced 
Bcl-2 phosphorylation (Wei et al., 2008). Recently, JNK signaling was 
shown to mediate amplification of ROS production during multiple stresses 
including infection (Chambers and LoGrasso, 2011). Cellular stress altered 
mitochondria, causing JNK to translocate to the mitochondria and to amplify 
up to 80% of the ROS generated largely by Complex I. ROS activates JNK 
via a sequence of events for JNK mitochondrial signaling (Chambers and 
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LoGrasso, 2011). There exists a molecular cross talk between autophagy and 
apoptosis, because Beclin 1 can be cleaved by caspases and its pro-
autophagic activity is lost (Djavaheri-Mergny et al., 2010). Moreover, the 
resulting C-terminal fragment of Beclin 1 could amplify mitochondrion-
mediated apoptosis (Djavaheri-Mergny et al., 2010; Wirawan et al., 2010). 
The kinase activity of MAPKs such as JNK is negatively regulated by 
DUSPs (also called MKPs). DUSP16/MKP-7 was found to work as a JNK-
specific phosphatase in vivo, because forced expression of DUSP16/MKP-7 
suppressed activation of MAPKs in the order of selectivity, JNK >> p38 > 
ERK (Masuda et al., 2001). When expressed in mammalian cells, 
DUSP16/MKP-7 was localized exclusively in the cytoplasm (Masuda et al., 
2001). Acetylation of the components of MAPK pathways on 
serine/threonine and lysine residues was previously reported to serve as a 
regulatory mechanism in biological signaling. Yersinia YopJ was shown to 
act as an acetyltransferase to modify serine and threonine residues in the 
activation loop of MAPK kinase-6 and thereby blocking phosphorylation 
and subsequent activation of the kinase activity (Mukherjee et al., 2006; 
Mukherjee et al., 2007). A nuclear-localized DUSP1/MKP-1 is acetylated by 
p300 on Lys57 within its docking domain, resulting in deactivation of Toll-
like receptor inflammatory signaling and inhibition of innate immune 
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signaling (Cao et al., 2008). p300 contains a histone acetyltransferase 
domain. Acetylation of DUSP1/MKP-1 enhanced its interaction with p38, 
thereby increased its phosphatase activity, and interrupted MAPK signaling 
cascade (Cao et al., 2008; Chi and Flavell, 2008). In this study, I have 
discovered that M. tuberculosis Eis acts as an N-acetyltransferase to 
acetylate Lys55 within the docking domain of DUSP16/MKP-7. I have also 
shown that M. tuberculosis Eis, but not M. smegmatis Eis, significantly 
down-regulated the LPS-induced JNK phosphorylation. On the basis of these 
findings, I propose that acetylation of DUSP16/MKP-7 by M. tuberculosis 
Eis is the key initial event in the JNK-dependent inhibition of autophagy, 
phagosome maturation, and ROS generation, which ultimately contributes to 
enhanced survival of M. tuberculosis within the macrophage cells. 
It has been well established that protein lysine acetylation critically 
regulates gene transcription by targeting histones as well as a variety of 
transcription factors in the nucleus (Close et al., 2010). Numerous proteins 
located outside the nucleus have also been demonstrated to be acetylated 
(Close et al., 2010). Indeed, protein lysine acetylation is emerging as a major 
mechanism by which key proteins are regulated in many physiological 
processes (Close et al., 2010). Recent reports also link lysine acetylation to 
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heterochromatin assembly, sister chromatid cohesion, cytoskeleton dynamics, 
autophagy, receptor signaling, RNA processing, and metabolic control (Kim 
and Yang, 2011). Proteomics studies indicate that the complexity of the 
acetylome potentially rivals that of the phosphoproteome (Norris et al., 
2009). Therefore, it is not surprising to find that M. tuberculosis utilizes Eis 
to acetylate the host signaling protein DUSP16/MKP-7 in suppressing 
immune responses for its survival in macrophages. M. tuberculosis might 
have evolved in such as way that its eis gene product has retained much of 
the aminoglycoside N-acetyltransferase activity, while it has gained a 
significantly higher protein lysine N-acetyltransferase activity to disrupt the 
cellular signaling pathway for intracellular survival. 
Similarly to M. tuberculosis Eis, protein kinase G (PknG) of M. 
tuberculosis inhibits phagosome-lysosome fusion and mediates intracellular 
survival of mycobacteria by disrupting the host cellular signaling (Walburger 
et al., 2004). PknG is one of the 11 eukaryotic-like Ser/Thr protein kinases 
encoded by the M. tuberculosis genome and is secreted within macrophages. 
M. tuberculosis Eis, like M. tuberculosis PknG, could be an excellent target 
for the development of drugs that induce mycobacterial death inside 
macrophages. An advantage of targeting Eis or PknG is that it does not kill 
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the bacteria per se but instead facilitates the macrophage to carry out its 
natural antibacterial activity, delivering intracellularly surviving 
mycobacteria to lysosomes for destruction (Nguyen and Pieters, 2009). 
Another potential advantage of targeting a secreted protein such as Eis or 
PknG is that its inhibitors are not required to be transported through the 
extremely impermeable mycobacterial cell wall. This may greatly improve 
the bactericidal activity of the compounds (Nguyen and Pieters, 2009). M. 
tuberculosis Eis has an extra advantage, because existing aminoglycoside 
drugs such as kanamycin and amikacin can be made effective by inhibiting 
its aminoglycoside N-acetyltransferase activity. Structural information would 
be useful in structure-based discovery of peptidomimetic or small molecule 




Figure 16. Proposed reaction mechanism for M. tuberculosis Eis 
mediated catalysis of DUSP16/MKP-7 
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결핵균 (Mycobacterium tuberculosis)는 결핵을 일으키는 것으로 
알려진 대표적 병원성 세균이다. 전세계 인구의 약 1/3 이 결핵균에 
감염되어 있으며 결핵으로 인하여 매년 수백만 명이 목숨을 잃는다. 
또한 최근에는 기존 항생제에 대한 내성을 가진 multidrug-resistant 와 
extensively drug-resistant 한 결핵균들의 등장으로 인하여 그 위험도가 
더욱 커지고 있다. 뿐만 아니라 결핵균은 오랜 시간 잠복하고 있다가 
인체의 면역력이 떨어졌을 때 활성화되기 때문에 치료를 위하여서는 
여러 종류의 항생제를 6-9 개월간 장기 복용하여야 한다. 따라서 더 
효과적인 결핵 치료제의 개발이 시급한 상태이다. 특히 결핵균이 
면역체계를 이겨 내고 인체 내 세포에서 살아남는다는 것이 곧 결핵균의 
병원성과 밀접한 관련이 있다. 그렇기 때문에 결핵균이 대식세포 안에서 
어떻게 살아남는 지를 이해하는 것이 매우 중요하다. 결핵균은 숙주세포 
내에서 살아남기 위하여 대식세포 내에서 일어나는 phagosomal 
maturation 과 autophagy 를 방해한다. 이러한 과정에 관여하는 결핵균 
단백질의 동정은 새로운 항생제 개발의 표적을 제공해 줄 것이다. 
결핵균의 Enhanced intracellular survival (Eis) 단백질을 비병원성인 
Mycobacterium smegmatis 에서 발현시키면 대식세포 내에서의 생존 
능력이 많이 향상된다는 연구 결과가 보고되었다. 결핵균 Eis 가 인체 내 
면역체계의 중요한 역할을 하는 proinflammatory cytokine 들의 
발현량을 조절하고, JNK pathway 를 통해 autophagy 를 저해 하는 
것으로 알려졌다. 또한 결핵균 Eis 가 aminoglycoside 계열의 항생제를 
acetylation 시킴으로서 항생제 내성을 유발한다는 보고가 있었다. 이에 
본인은 결핵균의 Eis 단백질, 그리고 이와 58%의 아미노산 
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서열 identity 를 가진 M. smegmatis Eis 단백질의 삼차원 구조 및 
기능의 비교 연구를 통해 결핵균의 Eis 가 어떻게 알려진 기능들을 
하는지 규명하였다. 
따라서 결핵균의 Eis 의 다른 기질이 있을 것으로 예상하였고 활성 
부위의 구조를 잘 비교하면 결핵균의 Eis 와 M. smegmatis 의 Eis 의 
기질 부착 부위에 큰 차이가 있음을 발견할 수 있었다. 즉 결핵균의 
Eis 의 기질 부착 부위는 좁고 긴 반면, M. smegmatis 의 Eis 의 기질 
부착 부위는 둥글게 파인 모양을 하고 있다. 따라서 결핵균 Eis 의 
기질로서 작용하지만 M. smegmatis 의 Eis 의 기질로는 작용하지 못하는 
기질이 있을 것으로 판단하고 기존 연구 결과를 토대로 결핵균 Eis 의 
기질을 탐색하였다. 그 결과 결핵균 Eis 가 JNK-specific phosphatase 인 
dual specificity phosphatase 16 (DUSP16)/MAPK phosphatase-7 
(MKP-7)의 kinase 상호작용 부위에 포함되어 있는 Lys55 를 아세틸화 
시키는 반면, M. smegmatis 의 Eis 는 아세틸화 시키지 못한다는 사실을 
알 수 있었다. 추가적인 실험을 통하여 결핵균 Eis 에 의한 아세틸화로 
인하여 DUSP16/MKP-7 과 JNK 간의 강화된 상호작용이 JNK 의 
autophosphorylation 에 의한 활성화를 저해하고, 결과적으로 인체 
대식세포 내 면역체계인 autophagosome 숙성과 autophagy 에 의한 
결핵균의 제거가 무력화된다는 모형을 제시하였다. 이러한 결과를 통해 
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Agmatine, which results from the decarboxylation of arginine by
arginine decarboxylase, is a metabolic intermediate in the biosynth-
esis of putresine and higher polyamines. The enzyme agmatinase
catalyses the hydrolysis of agmatine to putresine and urea. Recent
studies indicate that agmatinase plays important roles in mammals.
Human mitochondrial agmatinase shows a considerable level of
sequence similarity to bacterial agmatinases, including a putative
agmatinase from Deinococcus radiodurans. The putative agmatinase
from D. radiodurans has been overexpressed in Escherichia coli and
crystallized at 297 K using polyethylene glycol 3000 as a precipitant.
X-ray diffraction data were collected to 1.80 AÊ from a crystal grown
in the presence of Mn2+ and 1,6-hexanediamine. The crystals are
orthorhombic, belonging to the space group P212121, with unit-cell
parameters a = 81.77, b = 131.44, c = 168.85 AÊ ,  =  =  = 90. A
hexameric molecule is likely to be present in the asymmetric unit,
giving a crystal volume per protein weight (VM) of 2.15 AÊ
3 Daÿ1 and
a solvent content of 41.8%.
Received 22 April 2004
Accepted 2 August 2004
1. Introduction
Agmatine is an amine that is synthesized by
decarboxylation of l-arginine by arginine
decarboxylase (ADC; Reis & Regunathan,
2000). In bacteria, plants and invertebrates,
agmatine is hydrolyzed to putrescine, the
precursor of spermine, by agmatinase (agma-
tine ureohydrolase, EC 3.5.3.11; Reis &
Regunathan, 2000). In 1994, agmatine was
identi®ed as an endogenous ligand for the
imidazoline receptor and agmatinase and ADC
were subsequently identi®ed in mammalian
brain. Several lines of evidence indicate that
agmatinase may play important roles in
mammals, including the regulation of neuro-
transmitter-related functions (Reis & Regu-
nathan, 1998, 2000). The amino-acid sequences
of agmatinases indicate their homology to
arginases, suggesting a common evolutionary
origin (Ouzounis & Kyrpides, 1994; Perozich et
al., 1998). Compared with the wealth of struc-
tural data on arginases, little structural infor-
mation is available on agmatinases. The human
agmatinase gene encodes a 352-residue
protein with a putative mitochondrial targeting
sequence at the amino-terminus. Human
agmatinase has about 30% sequence identity
to bacterial agmatinases and <20% identity to
mammalian arginases. Residues required for
binding of Mn2+ at the active site in bacterial
agmatinases and other members of the argi-
nase superfamily are fully conserved in human
agmatinase (Mistry et al., 2002; Iyer et al.,
2002).
In order to understand the functional
differences between agmatinase and arginase
in structural terms and to better understand
the functional roles of agmatinase, we have
initiated three-dimensional structure determi-
nation of agmatinase. In this study, we have
overexpressed a putative agmatinase from
Deinococcus radiodurans, a 304-residue
protein of 35 751 Da, in Escherichia coli and
have crystallized it. Of the protein sequences in
the SWISS-PROT database, this enzyme shows
the highest level of sequence identity to human
mitochondrial agmatinase; the sequence iden-
tity is 37% over the region encompassing
residues 11±298. We report here its crystal-
lization conditions and preliminary X-ray
crystallographic data.
2. Experimental
2.1. Protein expression and purification
The putative agmatinase gene (DR0149)
was ampli®ed by the polymerase chain reaction
using the D. radiodurans genomic DNA as
template. The forward and reverse oligo-
nucleotide primers designed using the
published genome sequence (White et al.,
1999) were 50-G GAA TTC CAT ATG AGC
GGG CCG GCC CAC C-30 and 50-CCG CCG
CTC GAG GAC ATG GTC GAA CAC CTC
GCA C-30, respectively, where the bases in
bold represent the NdeI and XhoI restriction-
enzyme cleavage sites. The ampli®ed DNA was
inserted into the NdeI/XhoI-digested expres-
crystallization papers
sion vector pET-28b(+) (Novagen). This
vector construction adds an eight-residue
tag (LEHHHHHH) to the carboxyl-
terminus and a 20-residue tag (MGSSH-
HHHHHSSGLVPRGSH) to the amino-
terminus of the gene product in order to
facilitate protein puri®cation. The protein
was overexpressed in E. coli C41(DE3) cells
(Miroux & Walker, 1996). Cells were grown
at 310 K to an OD600 of 0.5 in Terri®c Broth
medium containing 50 mg mlÿ1 kanamycin
and protein expression was induced by
1.0 mM isopropyl--d-thiogalactopyrano-
side (IPTG). Cell growth continued at 293 K
for 18 h after IPTG induction and cells were
harvested by centrifugation at 4200g
(6000 rev minÿ1; Sorvall GSA rotor) for
10 min at 277 K. The cell pellet was resus-
pended in ice-cold lysis buffer (20 mM Tris±
HCl pH 7.9, 500 mM sodium chloride, 5 mM
imidazole and 1 mM phenylmethylsulfonyl
¯uoride) and homogenized with an ultra-
sonic processor. The crude lysate was
centrifuged at 70 400g (30 000 rev minÿ1;
Beckman 45Ti rotor) for 1 h at 277 K and
the recombinant protein in the supernatant
fraction was puri®ed in two chromato-
graphic steps. The ®rst step utilized the
hexahistidine tags by metal-chelate chro-
matography on Ni±NTA resin (Qiagen).
Next, gel ®ltration was performed on a
HiLoad XK 16 Superdex 200 prep-grade
column (Amersham Pharmacia) previously
equilibrated with buffer A (50 mM Tris±HCl
pH 7.5) containing 100 mM sodium chloride
and 1 mM manganese sulfate. The homo-
geneity of the puri®ed protein was assessed
by SDS±PAGE (Laemmli, 1970). The
protein solution was concentrated using an
YM10 ultra®ltration membrane (Amicon).
The protein concentration was estimated by
measuring the absorbance at 280 nm,
employing the calculated extinction coef®-
cient of 16 500 Mÿ1 cmÿ1 (SWISS-PROT;
http://www.expasy.ch/).
2.2. Crystallization and dynamic light
scattering
Crystallization was performed at 297 K by
the hanging-drop vapour-diffusion method
using 24-well tissue-culture plates. Each
hanging drop was prepared on a siliconized
cover slip by mixing equal volumes (6 ml
each) of the protein solution at 1.4 mM
concentration and the inhibitor 1,6-hexane-
diamine solution at 334 mM concentration,
resulting in an approximately 1:6.7 molar
ratio of the agmatinase monomer to inhi-
bitor. Each hanging drop was placed over
1.0 ml reservoir solution. Initial crystal-
lization conditions were established using
screening kits from Hampton Research
(Crystal Screens I and II and MembFac) and
from deCODE Biostructures Group
(Wizard I and II). Dynamic light-scattering
experiments were performed using a model
DynaPro-801 instrument from Protein
Solutions (Lakewood, New Jersey). The
data were measured at 297 K with the
protein at 1 mg mlÿ1 concentration in
50 mM Tris±HCl pH 7.5, 100 mM sodium
chloride and 1 mM manganese sulfate in the
presence of a 6.7-fold molar excess of
1,6-hexanediamine.
2.3. X-ray diffraction experiment
Crystals were ¯ash-frozen using a cryo-
protectant solution consisting of 100 mM
sodium phosphate citrate pH 4.2, 200 mM
sodium chloride, 12%(w/v) PEG 3000 and
15%(v/v) glycerol. Crystals were soaked in
5 ml of the cryoprotectant solution for 10 s
before being ¯ash-frozen in liquid nitrogen.
X-ray diffraction data were collected at
100 K using a DIP-2030 image-plate
detector (MacScience) at beamline BL-6B
of Pohang Light Source, South Korea. The
crystal was rotated through a total of 180
with a 1.0 oscillation range per frame. The
wavelength of the synchrotron radiation was
1.000 AÊ . The raw data were processed and
scaled using the HKL program package
(Otwinowski & Minor, 1997).
3. Results
When the recombinant agmatinase from
D. radiodurans was expressed in E. coli as a
fusion with the C-terminal eight-residue tag
(LEHHHHHH), the expression level was
very low. However, when the 20-residue tag
(MGSSHHHHHHSSGLVPRGSH) was also
fused at the N-terminus of the protein, it was
highly overexpressed in a soluble form, with
a much higher yield of 40 mg of puri®ed
enzyme per litre of culture. Dynamic light-
scattering analysis indicated the puri®ed
protein to be monodisperse with a poly-
dispersity of 20.5% and a native molecular
weight of 185 000 Da. This result is
consistent with D. radiodurans agmatinase
existing as a tetramer, pentamer or hexamer
in solution (the calculated monomer weight
including the N- and C-terminal tags is
35 751 Da).
Despite the presence of both N- and
C-terminal tags, the recombinant enzyme
readily formed well diffracting crystals. The
best crystals were obtained with a reservoir
solution comprising 100 mM sodium phos-
phate±citrate pH 4.2, 200 mM sodium
chloride, 12%(w/v) PEG 3000 and 30 mM
glycyl-glycyl-glycine. Rectangular crystals
grew to maximum dimensions of 0.15  0.15
 0.20 mm within two weeks (Fig. 1). A
¯ash-frozen crystal diffracted to 1.8 AÊ . A
set of diffraction data was collected with a
completeness of 98.0% to 1.80 AÊ and an
Rmerge of 7.1%. Table 1 summarizes the
statistics of data collection. The space group
was determined to be P212121 on the basis of
systematic absences and the unit-cell para-
meters are a = 81.77 (4), b = 131.44 (3),
c = 168.85 (3) AÊ ,  =  =  = 90, where
estimated standard deviations are given in
parentheses. If it is assumed that a
hexameric molecule of the recombinant
enzyme is present in the crystallographic
asymmetric unit, the crystal volume per
protein weight (VM) is 2.15 AÊ
3 Daÿ1 and the
solvent content is 41.8% by volume
(Matthews, 1968). This assumption is
supported by the self-rotation function,
which clearly indicated the presence of
threefold rotational symmetry. Hence, the
hexameric molecule must have 32 symmetry.
The structure has been determined by
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Figure 1
Crystals of the putative agmatinase from D. radio-
durans. Their approximate dimensions are 0.15 
0.15  0.20 mm.
Table 1
Data-collection statistics.
Values in parentheses refer to the highest resolution shell
(1.86±1.80 AÊ ).
X-ray wavelength (AÊ ) 1.000
Temperature (K) 100
Space group P212121
Unit-cell parameters (AÊ ) a = 81.77, b = 131.44,
c = 168.85
Resolution range (AÊ ) 30.0±1.80
Total/unique re¯ections 713493/164504
Rmerge² (%) 7.1 (39.6)
Data completeness (%) 98.0 (94.5)





i jIhi ÿ hIhij=
P
hhIhi, where I(h)i is
the intensity of the ith measurement of re¯ection h and hI(h)i
is the mean value of I(h) for all i measurements.
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be described elsewhere.
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N-terminal acetylation is one of the most common protein modifications in
eukaryotes, occurring in approximately 80–90% of cytosolic mammalian
proteins and about 50% of yeast proteins. ARD1 (arrest-defective protein 1),
together with NAT1 (N-acetyltransferase protein 1) and possibly NAT5, is
responsible for the NatA activity in Saccharomyces cerevisiae. In mammals,
ARD1 is involved in cell proliferation, neuronal development and cancer.
Interestingly, it has been reported that mouse ARD1 (mARD1225) mediates
"-acetylation of hypoxia-inducible factor 1 (HIF-1) and thereby enhances
HIF-1 ubiquitination and degradation. Here, the preliminary X-ray crystallo-
graphic analyses of two N-terminal acetyltransferase-related proteins encoded
by the Ta0058 and Ta1140 genes of Thermoplasma acidophilum are reported.
The Ta0058 protein is related to an N-terminal acetyltransferase complex ARD1
subunit, while Ta1140 is a putative N-terminal acetyltransferase-related protein.
Ta0058 shows 26% amino-acid sequence identity to both mARD1225 and human
ARD1235.The sequence identity between Ta0058 and Ta1140 is 28%. Ta0058 and
Ta1140 were overexpressed in Escherichia coli fused with an N-terminal
purification tag. Ta0058 was crystallized at 297 K using a reservoir solution
consisting of 0.1 M sodium acetate pH 4.6, 8%(w/v) polyethylene glycol 4000
and 35%(v/v) glycerol. X-ray diffraction data were collected to 2.17 Å. The
Ta0058 crystals belong to space group P41 (or P43), with unit-cell parameters
a = b = 49.334, c = 70.384 Å,  =  =  = 90. The asymmetric unit contains a
monomer, giving a calculated crystal volume per protein weight (VM) of
2.13 Å3 Da1 and a solvent content of 42.1%. Ta1140 was also crystallized at
297 K using a reservoir solution consisting of 0.1 M trisodium citrate pH 5.6,
20%(v/v) 2-propanol, 20%(w/v) polyethylene glycol 4000 and 0.2 M sodium
chloride. X-ray diffraction data were collected to 2.40 Å. The Ta1140 crystals
belong to space group R3, with hexagonal unit-cell parameters a = b = 75.174,
c = 179.607 Å, =  = 90,  = 120. Two monomers are likely to be present in the
asymmetric unit, with a VM of 2.51 Å
3 Da1 and a solvent content of 51.0%.
1. Introduction
N-terminal acetylation is one of the most common protein modifi-
cations in eukaryotes, occurring in approximately 80–90% of cyto-
solic mammalian proteins and about 50% of yeast proteins (Polevoda
& Sherman, 2003). Studies with Saccharomyces cerevisiae revealed
three major N-terminal acetyltransferases, NatA, NatB and NatC,
which exhibit different substrate specificities (Polevoda & Sherman,
2003). ARD1 (arrest-defective protein 1), together with NAT1
(N-acetyltransferase protein 1), is required for NatA activity in yeast
(Lee et al., 1989; Mullen et al., 1989; Park & Szostak, 1992). The yeast
N-terminal acetyltransferase complex NatA was quantitatively bound
to ribosomes via NAT1 and contained a third subunit, NAT5
(Gautschi et al., 2003). Human homologues of ARD1 and NAT1 also
form an evolutionarily conserved N-terminal acetyltransferase
complex (Arnesen, Anderson et al., 2005) and a human homologue of
NAT5 has also been identified (Arnesen, Anderson et al., 2006). In
mammals, the N-terminal acetyltransferase complex plays an impor-
tant role in cell proliferation, neuronal development and cancer
(Sugiura et al., 2003; Fisher et al., 2005; Arnesen, Gromyko et al.,
2005).
ARD1 and NAT5 proteins have been assigned to the ARD1
subfamily of acetyltransferases. They possess an acetyl-CoA-binding
# 2006 International Union of Crystallography
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motif (Q/R)XXGX(G/A) (Neuwald & Landsman, 1997; Arg82–
Ala87 in ARD1 and Arg84–Ala89 in NAT5 for both human and
mouse). A recent study has identified three mouse (mARD1198,
mARD1225 and mARD1235) and two human (hARD1131 and
hARD1235) variants of ARD1 (Kim et al., 2006). Of the ARD1
isoforms, mARD1225 differs completely in its C-terminal region
(residues 158–225) from mouse and human ARD1235 (Kim et al.,
2006). Interestingly, a mouse ARD1 variant (mARD1225) was
reported to mediate "-acetylation of Lys532 within the oxygen-
dependent degradation (ODD) domain of hypoxia-inducible factor
1 (HIF-1), thereby enhancing HIF-1 ubiquitination and degra-
dation (Jeong et al., 2002; Kim et al., 2006). However, other investi-
gators could not demonstrate such an activity for hARD1235 (Fisher
et al., 2005; Bilton et al., 2005). Overexpression or silencing of
hARD1235 had no impact on HIF-1 stability (Arnesen, Kong et al.,
2005) and the recombinant hARD1235 did not catalyze the acetylation
of HIF-1 ODD domain (Murray-Rust et al., 2006). In constrast,
Chang and coworkers recently provided strong evidence for the role
of hARD1 in HIF-1 stability in human cells (Chang et al., 2006).
They suggested that connective tissue-growth factor (CTGF) medi-
ated HIF-1 degradation was attributed to hARD1-dependent
acetylation of HIF-1 at Lys532 in human lung cancer cells (Chang et
al., 2006). Structurally, hARD1235 consists of a compact globular
region (residues 1–178) and a flexible unstructured C-terminus
(Sanchez-Puig & Fersht, 2006). The globular region encompasses the
predicted acetyltransferase domain of hARD1235 (residues 44–129;
Arnesen, Betts et al., 2006). It was also reported that hARD1235 forms
protofilament aggregates under physiological conditions of pH and
temperature (Sanchez-Puig & Fersht, 2006). In particular, the region
encompassing the acetyltransferase domain is responsible for fibre
formation (Sanchez-Puig & Fersht, 2006), which in turn may abrogate
the catalytic activity of hARD1235.
Despite the important functional role of protein N-terminal
acetyltransferases, their structural studies are in an early stage. To
provide a structural basis to obtain a better understanding of protein
N-acetylation by N-terminal acetyltransferases and to facilitate
structural comparisons with N"-acetyltransferases, we have initiated
three-dimensional structure determination of the Ta0058 gene
product from Thermoplasma acidophilum. Its 154-residue protein is
related to the N-terminal acetyltransferase complex ARD1 subunit.
It shows amino-acid sequence identity of 26% with mARD1225,
mARD1235 and hARD1235. We have also performed crystallization
studies of the Ta1140 gene product from T. acidophilum, a putative
N-terminal acetyltransferase-related protein. Its 149-residue poly-
peptide chain shows sequence identity of 28% with Ta0058, but bears
no detectable sequence homology with either mouse or human
ARD1 variants. As the first step toward structure determination of
the Ta0058 and Ta1140 proteins from T. acidophilum, we over-
expressed them in Escherichia coli and crystallized them. Here, we
report the crystallization conditions and preliminary X-ray crystallo-
graphic data. Both of these crystals are suitable for structure deter-
mination at sufficiently high resolution. It is hoped that the ultimate
structural information on these proteins will provide a framework for
obtaining a better insight into the molecular functions of N-terminal
acetyltransferase-related proteins.
2. Experimental
2.1. Protein expression and purification
The Ta0058 and Ta1140 genes were amplified by polymerase chain
reaction (PCR) using the genomic DNA of T. acidophilum as the
template and the following oligonucleotide primers, which were
designed using the published genome sequence (Ruepp et al., 2000).
The forward and reverse primers were 50-G GAA TTC CAT ATG
GCT ATA AAT GCT GTG GCC G-30 and 50-CCG CCG CTC GAG
TTA CTA AAC TAT GCG CCA CAT AGT GT A-30 for Ta0058 and
50-G GAA TTC CAT ATG ATC CTG AGA AGA TAC AGA AGT
ACG G-30 and 50-CCG CTC GAG TTA TCT GCA CAT CAA CCT
CAT TCT ATA-30 for Ta1140. The bases in bold represent the NdeI
and XhoI restriction-enzyme cleavage sites. The PCR product was
then digested with NdeI and XhoI and inserted into the NdeI/XhoI-
digested expression vector pET-28b(+) (Novagen). This vector
construction added a 20-residue tag (MGSSHHHHHHSSGLVPR-
GSH) to the N-terminus of the gene product in order to facilitate
protein purification.
The Ta0058 protein was expressed in E. coli Rosetta II(DE3)pLysS
cells. The cells were grown at 310 K to an OD600 of 0.5 in Terrific
Broth medium containing 30 mg ml1 kanamycin and protein
expression was induced by the auto-induction method (Studier,
2005). Cell growth continued at 303 K for 18 h after auto-induction
and cells were harvested by centrifugation at 4200g (6000 rev min1;
Sorvall GSA rotor) for 10 min at 277 K. The cell pellet was resus-
pended in ice-cold lysis buffer [5 mM imidazole, 500 mM sodium
chloride, 20 mM Tris–HCl pH 7.9, 5%(v/v) glycerol, 1 mM phenyl-
methylsulfonyl fluoride, 0.3%(v/v) Tween-20] and was then homo-
genized with an ultrasonic processor. The crude cell extract was
centrifuged at 36 000g (18 000 rev min1; Hanil Supra 21K rotor) for
60 min at 277 K and the recombinant protein in the supernatant
fraction was purified in two chromatographic steps. The first step
utilized the N-terminal hexahistidine tag by metal-chelate chroma-
tography on Ni–NTA resin (Qiagen). Gel filtration was then
performed on a HiLoad XK 16 Superdex 200 prep-grade column
(Amersham-Pharmacia) previously equilibrated with buffer A
(20 mM Tris–HCl pH 7.9) containing 200 mM sodium chloride. The
homogeneity of the purified protein was assessed by SDS–PAGE. The
protein solution was concentrated using a YM10 ultrafiltration
membrane (Millipore-Amicon). The protein concentration was esti-
mated by measuring the absorbance at 280 nm.
The Ta1140 protein was expressed in E. coli BL21(DE3)pLysS
cells. The cells were grown at 310 K to an OD600 of 0.6 in Terrific
Broth medium containing 30 mg ml1 kanamycin and protein
expression was induced by 0.5 mM isopropyl -d-thiogalacto-
pyranoside (IPTG). Cell growth continued at 293 K for 26 h after
IPTG induction and cells were harvested by centrifugation at 4200g
(6000 rev min1; Sorvall GSA rotor) for 10 min at 277 K. The cell
pellet was resuspended in ice-cold lysis buffer [5 mM imidazole,
500 mM sodium chloride, 20 mM Tris–HCl pH 7.9, 5%(v/v) glycerol,
1 mM phenylmethylsulfonyl fluoride] and was then homogenized
with an ultrasonic processor. The crude cell extract was centrifuged at
36 000g (18 000 rev min1; Hanil Supra 21K rotor) for 60 min at
277 K and the recombinant protein in the supernatant fraction was
purified in two chromatographic steps, essentially as above, except
that the gel-filtration buffer contained 2 mM -mercaptoethanol and
its pH was 7.0.
2.2. Crystallization
Crystallization trials were carried out at 297 K using the hanging-
drop vapour-diffusion method with 24-well VDX plates (Hampton
Research). Each hanging drop was prepared by mixing equal volumes
(2 ml each) of the Ta0058 protein solution (at 7.1 mg ml1 concen-
tration in a buffer consisting of 20 mM Tris–HCl pH 7.9, 200 mM
sodium chloride) and the reservoir solution. Each hanging drop was
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prepared by mixing equal volumes (2 ml each) of the Ta1140 protein
solution (at 6 mg ml1 concentration in a buffer consisting of 20 mM
Tris–HCl pH 7.0, 2 mM -mercaptoethanol and 200 mM sodium
chloride) and the reservoir solution. It was placed over 0.45 ml
reservoir solution. Screening of crystallization conditions was carried
out using commercial kits from Hampton Research (Crystal Screens I
and II, MembFac, Index I and II and SaltRX I and II) and from
Emerald Biostructures Inc. (Wizard I and II).
2.3. X-ray diffraction experiments
The reservoir solution used to crystallize Ta0058, which consisted
of 0.1 M sodium acetate pH 4.6, 8%(w/v) polyethylene glycol 4000
and 35%(v/v) glycerol, served as a cryoprotectant solution. There-
fore, the crystals could be flash-frozen by dipping into liquid nitrogen.
Ta1140 crystals were cryoprotected using a solution consisting of
95 mM trisodium citrate pH 5.6, 19%(v/v) 2-propanol, 19%(w/v)
polyethylene glycol 4000 and 5%(v/v) glycerol. The crystal was briefly
(10 s) soaked in the cryoprotectant solution and was flash-frozen by
dipping into liquid nitrogen. For Ta0058, we collected X-ray diffrac-
tion data at 100 K using a Quantum 315 CCD detector (Area
Detector System Corporation, Poway, CA, USA) at beamline BL-5A
of Photon Factory, Japan. The crystal was rotated through a total of
180 with a 1.0 oscillation range per frame. For Ta1140, X-ray data
were collected at 100 K using a Quantum 210 CCD detector (Area
Detector System Corporation, Poway, CA, USA) at beamline BL-4A
of Pohang Light Source, Korea. The crystal was rotated through a
total of 152. The raw data for both Ta0058 and Ta1140 were
processed and scaled using the HKL-2000 program package (Otwi-
nowski & Minor, 1997).
3. Results
When we expressed Ta0058 in E. coli strain BL21(DE3) as an intact
form, it was not expressed. When we expressed it as a fusion with the
N-terminal 20-residue tag (MGSSHHHHHHSSGLVPRGSH), it was
highly overexpressed but the protein was insoluble. When the
N-terminally tagged Ta0058 was expressed in Rosetta II(DE3)pLysS
cells, it was highly overexpressed and was mostly soluble. The yield
was 11 mg purified enzyme per litre of culture. When Ta1140 was
expressed as an intact form in the E. coli BL21(DE3)pLysS strain, the
protein was expressed at a very low level with poor solubility (below
10%). However, when we expressed it as a fusion with the N-terminal
20-residue tag in BL21(DE3)pLysS cells, the expression level was
much higher and 80% of the expressed protein was in the soluble
fraction. The yield was 8 mg of purified enzyme per litre of culture.
Despite the presence of the N-terminal tag, we could obtain well
diffracting crystals of both recombinant proteins.
The best crystallization conditions of Ta0058 were obtained after
optimizing the initial crystallization condition No. 37 of Crystal
Screen I (Hampton Research), with the refined reservoir solution
comprising 0.1 M sodium acetate pH 4.6, 8%(w/v) polyethylene
glycol 4000 and 35%(v/v) glycerol. The crystals grew to approximate
dimensions of 0.4  0.05  0.05 mm within a day (Fig. 1). The crystal
used for data collection diffracted strongly to 2.17 Å, but only very
weakly beyond this resolution. An X-ray diffraction data set was
collected to 2.17 Å and the crystals belonged to space group P41 (or
P43), with unit-cell parameters a = b = 49.334, c = 70.384 Å,
 =  =  = 90. One monomer is present in the crystallographic
asymmetric unit, with a calculated crystal volume per protein weight
(VM) of 2.13 Å
3 Da1 and a solvent content of 42.1%. Table 1
summarizes the X-ray data-collection statistics for Ta0058.
We grew the best crystals of Ta1140 after optimizing the initial
crystallization condition No. 40 of Crystal Screen I (Hampton
Research), with the refined reservoir solution comprising 0.1 M
trisodium citrate pH 5.6, 20%(v/v) 2-propanol, 20%(w/v) poly-
ethylene glycol 4000 and 0.2 M sodium chloride. The crystals grew to
approximate dimensions of 0.2  0.2  0.02 mm within 2 d (Fig. 1).
The crystals of Ta1140 diffracted more poorly than those of Ta0058.
Diffraction data were collected to 2.40 Å and the space group was
determined to be R3 on the basis of systematic absences and
diffraction intensity symmetry. The unit-cell parameters are
a = b = 75.174, c = 179.607 Å,  =  = 90,  = 120 in the hexagonal
setting. Two monomers are likely to be present in the asymmetric
crystallization communications
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Table 1
Data-collection statistics for Ta0058.
Values in parentheses are for the highest resolution shell.
X-ray source Photon Factory beamline BL-5A
X-ray wavelength (Å) 1.0000
Temperature (K) 100
Space group P41 (or P43)
Unit-cell parameters (Å, ) a = 49.334, b = 49.334, c = 70.384,
 = 90,  = 90,  = 90
Resolution range (Å) 50–2.17 (2.25–2.17)
Total/unique reflections 61931/8885
Rmerge† (%) 0.070 (0.182)
Data completeness (%) 99.0 (92.2)









i IðhÞi , where I(h)i is the intensity of the ith
measurement of reflection h and hI(h)i is the mean value of I(h) for all i measurements.
Table 2
Data-collection statistics for Ta1140.
Values in parentheses are for the highest resolution shell.
X-ray source Pohang Light Source beamline BL-4A
X-ray wavelength (Å) 0.9919
Temperature (K) 100
Space group R3
Unit-cell parameters (hexagonal setting)
(Å, )
a = 75.174, b = 75.174, c = 179.607,
 = 90,  = 90,  = 120
Resolution range (Å) 50–2.40 (2.49–2.40)
Total/unique reflections 74875/15318
Rmerge† (%) 0.053 (0.478)
Data completeness (%) 99.9 (99.7)
Average I/(I) 31.8 (3.26)
† Rmerge as in Table 1.
Figure 1
Crystals of N-terminal acetyltransferase-related proteins from T. acidophilum. (a)
Crystals of Ta0058. The large crystals have approximate dimensions of 0.4 0.05
0.05 mm. (b) Crystals of Ta1140. The large crystals have approximate dimensions of
0.2  0.2  0.02 mm.
unit, giving a VM of 2.51 Å
3 Da1 and a solvent content of 51.0%.
Table 2 summarizes the X-ray data-collection statistics for Ta1140.
We thank the staff of beamlines BL-5A, BL-6A and NW-12A of
Photon Factory, Tsukuba, Japan and beamlines BL-4A and BL-6B of
Pohang Light Source, Korea for assistance during X-ray experiments.
This work was supported by a grant from the Center for Functional
Analysis of Human Genome to SWS and by the Creative Research
Initiatives (NeuroVascular Coordination Research Center) of
MOST/KOSEF, Korea to KWK. SHH, JYH, KHK, OSJ, DJK and
JYK are recipients of BK21 fellowships.
References
Arnesen, T., Anderson, D., Baldersheim, C., Lanotte, M., Varhaug, J. E. &
Lillehaug, J. R. (2005). Biochem. J. 386, 433–443.
Arnesen, T., Anderson, D., Torsvik, J., Halseth, H. B., Varhaug, J. E. &
Lillehaug, J. R. (2006). Gene, 371, 291–295.
Arnesen, T., Betts, M. J., Pendino, F., Liberles, D. A., Anderson, D., Caro, J.,
Kong, X., Varhaug, J. E. & Lillehaug, J. R. (2006). BMC Biochem. 7, 13.
Arnesen, T., Gromyko, D., Horvli, O., Fluge, O., Lillehaug, J. & Varhaug, J. E.
(2005). Thyroid, 15, 1131–1136.
Arnesen, T., Kong, X., Evjenth, R., Gromyko, D., Varhaug, J. E., Lin, Z., Sang,
N., Caro, J. & Lillehaug, J. R. (2005). FEBS Lett. 579, 6428–6432.
Bilton, R., Mazure, N., Trottier, E., Hattab, M., Déry, M. A., Richard, D. E.,
Pouysségur, J. & Brahimi-Horn, M. C. (2005). J. Biol. Chem. 280, 31132–
31140.
Chang, C. C., Lin, M. T., Lin, B. R., Jeng, Y. M., Chen, S. T., Chu, C. Y., Chen,
R. J., Chang, K. J., Yang, P. C. & Kuo, M. L. (2006). J. Natl Cancer Inst. 98,
984–995.
Fisher, T. S., Etages, S. D., Hayes, L., Crimin, K. & Li, B. (2005). J. Biol. Chem.
280, 17749–17757.
Gautschi, M., Just, S., Mun, A., Ross, S., Rucknagel, P., Dubaquie, Y.,
Ehrenhofer-Murray, A. & Rospert, S. (2003). Mol. Cell Biol. 23, 7403–7414.
Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo,
M. A., Song, E. J., Lee, K. J. & Kim, K. W. (2002). Cell, 111, 709–720.
Kim, S. H., Park, J. A., Kim, J. H., Lee, J. W., Seo, J. H., Jung, B. K., Chun, K. H.,
Jeong, J. W., Bae, M. K. & Kim, K. W. (2006). Biochem. Biophys. Res.
Commun. 340, 422–427.
Lee, F. J., Lin, L. W. & Smith, J. A. (1989). J. Bacteriol. 171, 5795–5802.
Mullen, J. R., Kayne, P. S., Moerschell, R. P., Tsunasawa, S., Gribskov, M.,
Colavito-Shepanski, M., Grunstein, M., Sherman, F. & Sternglanz, R.
(1989). EMBO J. 8, 2067–2075.
Murray-Rust, T. A., Oldham, N. J., Hewitson, K. S. & Schofield, C. J. (2006).
FEBS Lett. 580, 1911–1918.
Neuwald, A. F. & Landsman, D. (1997). Trends Biochem. Sci. 22, 154–155.
Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326.
Park, E. C. & Szostak, J. W. (1992). EMBO J. 11, 2087–2093.
Polevoda, B. & Sherman, F. (2003). Biochem. Biophys. Res. Commun. 308,
1–11.
Ruepp, A., Graml, W., Santos-Martinez, M. L., Koretke, K. K., Volker, C.,
Mewes, H. W., Frishman, D., Stocker, S., Lupas, A. N. & Baumeister, W.
(2000). Nature (London), 407, 508–513.
Sanchez-Puig, N. & Fersht, A. R. (2006). Protein Sci. 15, 1968–1976.
Studier, F. W. (2005). Protein Expr. Purif. 41, 207–234.
Sugiura, N., Adams, S. M. & Corriveau, R. A. (2003). J. Biol. Chem. 278,
40113–40120.
crystallization communications
1130 Han et al.  N-terminal acetyltransferase-related proteins Acta Cryst. (2006). F62, 1127–1130
For structural studies by x-ray crystallography and nuclear magnetic resonance 
it is important for the target protein to be available in large quantity and 
high purity. Escherichia coli expression systems remain the most versatile 
and convenient means to produce a large quantity of recombinant proteins. 
Unfortunately, some proteins fail to be expressed in E. coli or are expressed in 
an insoluble form. To overcome the difficulty of no expression or expression 
at a very low level, a simple and efficient approach of screening a library of 
variants of a target protein with randomized N-termini was devised. In this 
method, a few N-terminal residues are randomized by designing a mixture 
of oligonucleotides for the forward PCR primer and fuse the library in front 
of green fluorescent protein, which serves as a reporter for the target protein 
expression level and folding yield. In favorable cases this approach can result 
in high-level soluble expression of recombinant proteins in E. coli. This 
chapter describes the results of a test of this approach with a bacterial protein 
(the HI0952 gene product) that is not well expressed in E. coli.
1. Introduction
Production of properly folded proteins or their isolated domains is a pre-
requisite for the detailed structural and functional characterization. For 
instance, structural studies of proteins by x-ray crystallography or nuclear 
magnetic resonance normally require significant amounts (5–50 mg) of a 
target protein in high purity. This is most often accomplished by expres-
sion of the target protein in soluble form using a suitable heterologous 
host. Escherichia coli is still the first choice for protein expression as it 
offers many advantages over other expression hosts in terms of speed, cost 
effectiveness, and convenience. Many expression vectors for heterologous 
expression in E. coli are already available and new vectors continue to be 
developed.
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E. coli has some limitations as an expression host. One of the limitations is 
that some proteins fail to be expressed in E. coli or their level of expression 
or solubility is very low when they are expressed. Causes of such failure in 
protein expression in E. coli may include the toxicity of the target protein, 
improper protein folding, the codon usage problem, instability of the mRNA, 
susceptibility of the expressed protein to proteolysis, and the hairpin formation 
at the 5'-side of the mRNA. Several strategies are available to overcome some 
of these difficulties. Rosetta cells (Novagen) provide tRNAs corresponding 
to infrequently used codons. C41 and C43 cells, derivatives of BL21, were 
isolated for producing toxic proteins (1). mRNA secondary structures at the 
5'-side can be minimized by silent mutations of the gene (2).
Alterations at the N-terminus of the target protein are well known to affect 
heterologous protein expression (3–6). It was observed that NGG codons at 
positions +2, +3, and +5 downstream of the initiation codon lower the gene 
expression in E. coli at the translational level and it has been suggested that 
the low expression is not the result of mRNA secondary structure or a lowered 
intracellular mRNA pool (7). As a specific example of altering the N-terminal 
region for enhancing the expression level, sequences within the first seven 
amino acid codons of the eukaryotic membrane protein (bovine cytochrome 
P450 17α-hydroxylase) were altered to optimize the expression in E. coli 
(8). However, such methods are time consuming and usually require a large 
number of trials.
Here a simple and efficient approach was devised to reducing the problem 
of no expression or very low-level expression in E. coli. In this method, few 
N-terminal residues of the target protein were randomized by employing a mix-
ture of oligonucleotides as the 5'-primer for polymerase chain reaction (PCR) 
and fuse the library in front of green fluorescent protein, which is used as the 
reporter for the expression level and folding yield. Then the library of the target 
protein with randomized N-terminus is screened for the clones that express the 
target protein at high levels in a soluble form. In favorable cases this approach 
has the potential to enable expression of the recombinant protein in E. coli 
both at a sufficiently high level and in a soluble form. This approach was tested 
with a bacterial protein (HI0952 gene product) that was not well expressed in 
E. coli. GFP fusions can be expressed in a variety of cell types, so in principle 
this method is applicable to protein expression in other hosts, provided that 
methods for highly efficient transformation of host cells are available.
2. Materials
2.1. Enzymes and Proteins
1. T4 DNA ligase (Takara, Shiga, Japan)
2. NdeI (DCC Bionet, Sungnam, Korea)
3. BamHI (DCC Bionet, Sungnam, Korea)
4. High-fidelity thermophilic DNA polymerase (Phusion DNA polymerase 
from Finnzymes, Keilaranta, Finland)
2.2. Plasmids, Nucleotides, Gels, and Kits
1. Green fluorescent protein (GFP) folding reporter vector (X-FR) (9)
2. pET-21a(+) (Merck, Darmstadt, Germany)
Kobe_Ch11.indd   188 9/14/2007   5:14:02 AM
Chapter 11 Proteins with Randomized N-termini 189
3. Oligonucleotide primers (Bioneer, Daejon, Korea) (see Note 1)
4. Template DNA for PCR: For cloning the HI0952 gene, the genomic DNA 
was obtained from ATCC
5. 1% (w/v) Agarose gel (Bioworld, Dublin, OH)
6. 12.5% (w/v) SDS-PAGE gel
7. Qiaquick spin gel extraction kit (Qiagen, Hilden, Germany)
2.3. Cells and Media
1. E. coli strain ElectroMAX DH10B (Invitrogen, Grand Island, NY)
2. E. coli strain BL21(DE3) (Invitrogen)
3. E. coli strain Rosetta II(DE3)pLysS (Invitrogen)
4. Luria-Bertani (LB) medium (BD Sciences, Franklin Lakes, NJ)
5. Kanamycin stock solution (35 mg/ml): 1.75 g of kanamycin in 50 ml of ster-
ile water. Aliquot in 1 ml fractions and store at −20°C
6. Isopropyl-β-D-thio-galactopyranoside (IPTG) stock solution (1.0 M): 4.8 g 
IPTG in 20 ml of sterile water. Aliquot in 1 ml fractions and store at −20°C
7. SOC: 2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose
2.4. Equipment
1. Microcentrifuge
2. PCR machine (MJ Research Model PTC-200)
3. MicroPulser electroporation apparatus (Bio-Rad, Hercules, CA)
4. Gene Pulser cuvette: 0.2 cm electrode gap (Bio-Rad, catalog no. 165–2086)
5. Nitrocellulose membrane, polyester reinforced (GE Osmonics, Minnetonka, 
MN): 85 mm, 137 mm diameter
6. Kirby-Bauer plate: 90 mm, 150 mm diameter
7. Illumatool tunable lights system, 488 nm excitation filter and 520 nm emis-
sion filter (Lightools Research, Encinitas, CA)
8. Digital camera with a stand
3. Methods
3.1. Library Construction of the Target Protein with Randomized 
N-Terminus
1. For the forward primer, design a mixture of oligonucleotides that contain 
NNY for the positions +2, +3, and +4 downstream of the translation initia-
tion codon, where N is any base (A, T, G, or C) and Y is a pyrimidine base 
(C or T) (see Notes 1 and 2).
2. Amplify the target gene by running the PCR reaction (see Note 3).
3. The PCR product is digested with NdeI and BamHI.
4. The digested PCR product is inserted into the NdeI/BamHI-digested GFP 
folding reporter vector by T4 DNA ligase.
3.2. Amplification of Library Plasmid
The GFP folding reporter vector containing the library of the target protein 
with randomized N-terminus is transformed into the E. coli nonexpression 
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strain DH10B by the electroporation method (see Note 4) and the amount 
of the plasmid library is amplified. The amplified plasmid library is then 
isolated for transformation into the E. coli expression strain BL21(DE3) by 
the chemical method. The following protocols for library transformation and 
recovery of the amplified library are a slight modification of those already 
described by Waldo (10).
3.2.1. Library Transformation into DH10B by Electroporation
 1. Thaw 100 µl aliquot of DH10B cells on ice (10–15 min).
 2. Prechill 100 µl dd H2O on ice (10 min) and three Gene Pulser cuvettes per 
library.
 3. Combine 100 µl thawed DH10B and 50 µL pre-chilled dd H2O, add the 
diluted DH10B to same tube on ice containing the 10 µL resuspended, 
ligated DNA, flick to gently mix, incubate 5 min on ice.
 4. Transfer 50 µL of transformation mix in each Gene Pulser cuvette (see 
Note 4).
 5. Recover each of the three transformations by immediately resuspending in 
1 ml SOC in 12 ml culture tube with shaking at 37°C for 1.5 hours.
 6. Centrifuge the recovered cultures in 1.5-ml Eppendorf tubes for 1 min at 
14,000 rpm.
 7. Leave 200 µL of supernatant over the pelleted cells (remove ~ 800 µl 
supernatant). Resuspend cells by pipetting.
 8. Pool the three tubes into one 1.5-ml Eppendorf. The total volume will be 
about 600 µl.
 9. Plate the library onto a large Kirby-Bauer plate (150 mm) selective media 
LB plate supplemented with 35 µg/ml kanamycin (LB-Kan).
10. On a separate counting agar plate, plate 1/300th of library (2 µl of the 600 µl 
pooled transformations into pool of ~ 200 µl SOC onto a standard LB/Kan 
selective plate to get the counts). Incubate 12–16 hours at 37°C (see Note 5).
3.2.2. Library Plasmid Recovery
1. Add 12 ml LB to the Kirby-Bauer DH10B library plate from plates in 
Section 3.2.1., resuspend with spreader.
2. Transfer suspension to 15-ml Falcon tube, vortex to suspend.
3. Perform QIAgen plasmid prep on 750 µl of cell suspension. Cell mass 
prepped should be equivalent to 3 ml of overnight LB culture, i.e., approx. 
75–100 mg pellet.
3.3. Screening of the Clones on the Basis of Gfp Fluorescence
1. Prepare nitrocellulose membranes (137 mm).
2. Label then wet the membranes (see Note 6). Place on towels to dry until 
damp only.
3. Lay on an LB-Kan Kirby-Bauer plate (150 mm), excluding all air pockets.
4. Incubate at 37°C for at least 1 hour prior to plating.
5. The plasmid library (1 µl) is transformed into BL21(DE3) competent cells 
(50 µl) by the heat shock protocol (42°C, 1 min) (see Note 7).
6. The transformed cells are plated directly onto nitrocellulose membranes 
(137 mm) on an LB-agar plate (150 mm). After the membrane is dry, invert 
the plate, and incubate at 37°C for 10–15 hours until colonies are approximately 
1 mm in diameter (see Note 7).
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 7. After incubation, the membrane is transferred onto an LB-agar plate 
(150 mm) containing 2 mM IPTG and is incubated for 5–6 hours for 
induction.
 8. Pick the 30 brightest colonies and transfer them onto the master LB-agar 
plate (90 mm).
 9. The master LB-agar plate (90 mm) is incubated at 37°C for 14–16 hours 
and its replica is made on a nitrocellulose membrane (85 mm).
10. The replica membrane is incubated on an LB-agar plate (90 mm) at 37°C 
for 8–10 hours, transferred onto an LB-agar plate containing 2 mM IPTG, 
and incubated for an additional 4–6 hours for induction.
11. Select colonies showing significant fluorescence improvements over the 
wild-type and the cell mass of the selected colonies on the plate is recov-
ered. For HI0952, we selected 13 colonies (Fig. 11.1).
3.4. Test of Protein Expression as a Fusion with GFP
1. The selected variant colonies are overexpressed in BL21(DE3) cells.
2. Cells are grown at 37°C up to OD600 of 0.5 in LB medium containing 35 µg/
ml kanamycin.
3. The protein expression is induced by 1.0 mM IPTG.
4. Cells are grown for additional 18 hours at 30°C.
5. The expression levels of the GFP fusion protein for the selected colonies are 
estimated by running SDS-PAGE on the total E. coli proteins.
6. Choose a few colonies that have a reasonably high expression level. As an 
example, six colonies were chosen for HI0952 (colonies #2, #3, #5, #6, #8, 
and #13 in Fig. 11.1).
7. The solubility of the GFP fusion protein for the selected colonies is esti-
mated by running SDS-PAGE on the soluble and insoluble fractions of the 
total E. coli proteins (see Note 8).
Fig. 11.1 Colonies of the selected HI0952 variants showing significant fluorescence 
improvements over the wild type, whose GFP fusion is almost nonfluorescent. Among 
these 13 colonies, colonies #2, #3, #5, #6, #8, and #13 were chosen for further character-
ization. The wild type colony is not included in this figure, because it is invisibly dark.
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8. Choose a colony that has both a high degree of soluble expression and a 
reasonably high expression level. As an example, the colony #3 was chosen 
for HI0952 (Fig. 11.2).
9. Purify the GFP folding reporter plasmid containing the desired variant.
3.5. Test of Protein Expression Without GFP Fusion
 1. The variant gene is amplified by high-fidelity PCR using the purified GFP 
plasmid as the template and the appropriate primers (see Note 9) for sub-
cloning into an expression vector without GFP fusion.
 2. The amplified PCR product is digested with NdeI and BamHI.
 3. The digested PCR product is inserted into the pET-21a(+) expression vec-
tor, which has been already digested with the same restriction enzymes.
 4. The plasmid pET-21a(+) carrying the desired variant gene is transformed 
into BL21(DE3) cells by the standard calcium chloride method.
 5. The transformed cells are grown at 37°C up to OD600 of 0.5 in LB medium 
containing 35 µg ml−1 kanamycin.
 6. The protein expression is induced by 1.0 mM IPTG.
 7. Cells are grown for additional 18 hours at 30°C.
 8. The expression level and solubility of the variant protein are assessed by 
running SDS-PAGE on soluble and insoluble fractions of the total E. coli 
protein. An example of SDS-PAGE analysis is shown in Fig. 11.3.
 9. The mutations introduced to the N-terminus are determined by performing 
DNA sequencing (see Note 10).
10. If necessary, the conditions for soluble expression of the variant protein can 
be further optimized, for example, by expressing it in different E. coli cells 
(e.g., BL21(DE3)pLysS or Rosetta II (DE3)pLysS) or at lower temperatures 
(e.g., 15°C). The variant protein can be evolved for further improvement in 
solubility using the split-GFP in vivo solubility reporter system (11).
4. Notes
1. Primer sequences designed for PCR (sub)cloning of the HI0952 gene are 
as follows. The underlined bases represent NdeI and BamHI digestion sites. 
The rare codon CGG was changed for Arg2 into CGT in the forward primer 
#1b for the wild-type to reduce the codon usage problem.
Fig. 11.2 SDS-PAGE analysis of HI0952 variants with C-terminally fused GFP. The 
colony #3 shows both bright fluorescence and a high expression level.
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 • #1a (Forward primer for constructing a library of proteins with randomized 
N-terminus):
G GAA TTC CAT ATG NNY NNY NNY TCT TTC TTA TTT TTC TTT 
TAT AAA TAT ATG (52-mer), where N is any base (A, T, G, or C) and Y 
is a pyrimidine base (C or T).
 • #1b (Forward primer for wild type):
G GAA TTC CAT ATG CGT TCA AAA TCT TTC TTA TTT TTC TTT 
TAT AAA TAT ATG (52-mer).
 • #2 (Reverse primer for both wild type and the variant library; reverse 
primer for subcloning the selected variant into pET-21a(+)):
CGC CGC GGA TCC TAA TAA ACA ATT CTC CGC GAA AGA A 
(37-mer).
 • #3 (Forward primer for subcloning the selected variant into pET-21a(+)):
CTA ATA CGA CTC ACT ATA GGG G (22-mer). This primer covers a 
T7 promoter region.
2. By limiting the third position of the codon to be either C or T we 
can avoid introducing stop codons and some of the rare codons in E. 
coli. That is, we exclude all codons for five amino acids (methionine, 
glutamine, glutamate, lysine, and tryptophan) and stop codons by limit-
ing the codon to NNY. The designed primer mixture contains (4 × 4 × 
2)3 = 32,768 sequences, which correspond to (15 × 15 × 15) = 3,375 
protein sequences. By limiting the codon to NNY, we also exclude 
the NGG codons at positions +2 and +3, which were found to lower 
the gene expression in E. coli at the translational level (7). It is reason-
able to assume that the structure and function of the recombinant protein 
will be affected only insignificantly by altering the second, third, and 
fourth amino acids in most cases. This is because the altered positions 
are generally variable in sequence.
3. For HI0952, we used the following protocol (“touchdown” PCR) pro-
grammed into a MJ Research Model PTC-200 PCR machine:
 Step 1: 98°C, 30 seconds
 Step 2: 98°C, 10 seconds
Fig. 11.3 SDS-PAGE analysis of HI0952 wild-type and variants (nonfusion), which 
are indicated by the arrows on the right side of each gel. The #3 variant shows the best 
solubility compared to other variants and the wild-type. I–, before IPTG induction; I+, 
after IPTG induction; P, pellet fraction; S, supernatant fraction.
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 Step 3: 50°C, 20 seconds (Increase the temperature by 1°C per cycle.)
 Step 4: 72°C, 20 seconds*
 Step 5: Steps 2 through 4 are repeated 15 times
 Step 6: 98°C, 10 seconds
 Step 7: 58°C, 20 seconds
 Step 8: 72°C, 20 seconds*
 Step 9: Steps 6–8 are repeated 30 times.
 Step 10: 72°C, 5 minutes
 Step 11: 4°C
Details of the PCR reaction mixture:
 35 µl ddH2O
 10 µl 5 × High-fidelity buffer (Finnzymes)
 1.0 µl 10 mM dNTPs (2.5 mM each dNTP)
 0.5 µl Phusion DNA polymerase (Finnzymes)
 0.5 µl Forward primer (100 pmol/µl stock)
 0.5 µl Reverse primer (100 pmol/µl stock)
 1.0 µl Template DNA (50 ng/µl)
 1.5 µl DMSO
 50 µl Total volume
4. Set electroporator to 2.5 kV. If arcing occurs and is outside the cuvette, 
recover mix and perform pulse in a fresh cuvette.
5. If fewer than 200 colonies are observed on the counting plate, the variant 
library may not be as complete as desired. In such a case, try to adjust the 
ratio of the GFP folding reporter plasmid to the PCR product to obtain more 
than 200 colonies.
6. It is necessary to preincubate the nitrocellulose membrane in distilled water 
for 5 minutes in order to avoid formation of air bubbles between the mem-
brane and the plate, which adversely affect the growth of the colonies.
7. Depending on the competency of the BL21(DE3) strain, 1 µl of a “standard” 
plasmid prep could yield several hundred thousand colonies. One option is to 
make the BL21(DE3) expression library essentially a lawn, then washing the 
viable cells off the plate and diluting sequentially twice 350-fold and plating 
1 ml of this per Kirby-Bauer plate (150 mm) for actually picking. This would 
add one extra step per day. Otherwise, one could do a set of dilution plates in 
step 6 of Heading 3.3, and use the one showing single colonies for picking. 
Since the library size is relatively small, this places an estimate on the number 
of clones needed to get good representation (see Note 5).
8. Fluorescence of the C-terminal GFP in the fusion context reflects the 
expression level of the fusion protein as well as the lack of misfolding by 
the upstream fusion partner protein. Therefore, increased fusion fluores-
cence is correlated with increased expression and solubility of the test 
protein in the nonfusion context. Note that GFP-fusions can have reduced 
solubility, so it is essential to test the solubility of the selected protein 
 variants without the fused GFP.
* For Phusion DNA polymerase (Finnzymes), the supplier recommends an extension 
time of 15 seconds per 1 kb for low complexity DNAs (e.g., plasmid, lambda, or BAC 
DNA) and 30 seconds per 1 kb for high-complexity genomic DNAs. A longer extension 
time than recommended by the supplier is preferred for this PCR reaction.
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 9. Forward primer: #3 primer (see Note 1). Reverse primer: #2 primer (see 
Note 1).
10. Results of DNA sequencing of some variants of HI0952 are as follows.
  Wild-type: ATG CGT TCA AAA (MRSK)
  Colony #2: ATG ACC TGT GAC (MTCD)
  Colony #3: ATG CGC TGT TGC (MRCC)
  Colony #8: ATG GGC CTT GCC (MGLA)
  Colony #13: ATG GGT CTT GAT (MGLD)
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INTRODUCTION
p97/valosin-containing protein (VCP) is an ATPase of
the AAA1 family and has been implicated in diverse cel-
lular processes: post-mitotic Golgi reassembly, endoplas-
mic reticulum associated degradation, nuclear envelope
reconstruction, cell cycle, suppression of apoptosis, and
DNA damage response.1 AAA1 family members are clas-
sified into two subgroups of Type I and Type II on the
basis of the number of ATPase domains included. Type II
contains two ATPase domains, referred to D1 and D2
domains, and Type I contains only one ATPase domain,
termed D2. In addition to the ATPase domains, less con-
served domains are often found at the N-terminus (N
domain) or the C-terminus of many AAA1 family pro-
teins, and those terminal domains are involved in bind-
ing to adaptor proteins. p97/VCP belongs to the Type II
subgroup and is comprised of the N, D1, and D2
domains, respectively. Structural studies have shown that
p97/VCP forms a homo-hexamer through D1 and D2
domains, and the N domain is located at the perimeter
of the hexameric ring.2–4
p97/VCP accomplishes its various functions through
recruiting different adaptor proteins. Proteins containing
the UBX domain such as Fas-associated factor 1 (FAF1)
and p47 form the largest group of the adaptors.5,6 The
UBX domain is a general p97/VCP-binding module,7
and its structures were determined by NMR spectroscopy
on FAF1 UBX and p47 UBX.6,8 The UBX domain adopts
a b-grasp fold similar to ubiquitin and its conserved FP
sequence motif in the loop connecting strands S3 and S4
(so called S3/S4 loop) is inserted into the cleft of the
p97/VCP N domain as shown in the crystal structure of
p47 UBX in complex with p97/VCP ND1 fragment at 2.9
Å resolution.9 Very recently, we reported the crystal
structure of FAF1 UBX, revealing that the very S3/S4
loop containing the FP sequence adopts a cis-Pro touch-
turn structure, a rare case of open b-turn, and the pep-
tide bond between these two residues is a cis peptide, so
named as FcisP touch-turn motif.10
FAF1, initially identified as a Fas-interacting protein,
inhibits the proteasome-mediated protein degradation
process either by interacting with p97/VCP which may
serve as a molecular chaperone presenting the ubiquiti-
nated client proteins to the proteasome or by interacting
with ubiquitinated client proteins.5 Human FAF1, com-
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posed of 650 amino acid residues, contains five domains:
UBA at the N-terminus, two tandem UBLs, UAS, and
UBX at the C-terminus.5,11 Among those five, the two
very terminal domains, UBA and UBX, are implicated in
proteasome-mediated protein degradation. The N-termi-
nal UBA domain interacts with ubiquitins conjugated to
the client proteins and the C-terminal UBX domain
binds to the N domain of p97/VCP. Through these two
kinds of interactions implicated in the proteasome-medi-
ated protein degradation, FAF1 inhibits the protein deg-
radation and consequently enhance the cell death.5
In an effort to elucidate the conserved structural fea-
tures of the UBX domain as a general p97/VCP-binding
module and also to provide a structural basis of the
interaction between FAF1 and p97/VCP, we have carried
out X-ray crystallographic structure analyses of FAF1
UBX domain in complex with p97/VCP N domain. Here,
we report its crystal structure at 2.2 Å resolution, reveal-
ing conformational changes of FAF1 UBX domain on
binding.
MATERIALS AND METHODS
Data collection and structure determination
The human FAF1 UBX domain (residues 571–650)
and the human p97/VCP N domain (residues 21–196)
were overexpressed, purified, and crystallized as described
previously.12,13 We collected X-ray diffraction data at
2.2 Å resolution at Photon Factory, Japan on the beam-
line BL-17A. The structure was solved by the molecular
replacement using Phaser in CCP4 program suite.14,15
The search model for FAF1 UBX domain was its previ-
ously reported NMR structure (PDB code 1H8C).8 For
the p97/VCP N domain, the corresponding part (residues
23–196) was taken from the crystal structure of p97/VCP
ND1 in complex with p47 UBX (PDB code 1S3S).9
Domains were located in the order of p97/VCP N do-
main and FAF1 UBX. Subsequent manual model rebuild-
ing was carried out using Coot16 interspersed with
rounds of automatic refinement by Refmac517 and
CNS.18 Geometry of the final refined model was checked
with MolProbity.19 Statistics for data collection and
structure refinement is summarized in Table I. Structure
factors and the final refined coordinates have been de-
posited in the Protein Data Bank with an accession num-
ber 3QC8.
Site-directed mutagenesis
Four single mutants (R579A, F619S, R621A, and
F645S) and two double mutants (F619S/R621A and
F619S/F645S) of FAF1 UBX were prepared using the
method of the QuikChange Site-Directed Mutagenesis kit
(Stratagene, USA). The mutations were confirmed by
sequencing (Bionics, Korea).
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments
were performed using a VP-ITC instrument (MicroCal,
USA). Recombinant protein samples were dialyzed into
50 mM Tris-HCl (pH 7.4), 150 mM KCl, 5 mM MgCl2,
and 10% (v/v) glycerol before titration. Titrations were
carried out by injecting consecutive aliquots of FAF1
UBX wild type or mutants (1 mM) protein sample into
the ITC cell containing p97/VCP N domain sample (0.05
mM) at 258C. Binding stoichiometry, enthalpy, entropy,
and binding constants were determined by fitting the
data to a one-site binding model. The ITC data were fit
using Origin 7.0 (MicroCal, USA).
RESULTS AND DISCUSSION
Structure of FAF1 UBX in complex with
p97/VCP N domain
The asymmetric unit of the crystal contains a single
copy of 1:1 complex between FAF1 UBX domain and
p97/VCP N domain. The refined model of the complex
contains residues Glu571 to Glu650 of FAF1 UBX and
residues Pro23 to Glu192 of p97/VCP N domain. FAF1
UBX domain comprises five b-strands (S1–S5), one
a-helix (H1), and three 310 helices (G1–G3) [Fig. 1(A)].
The five strands form a mixed b-sheet in the order of
21534, and the sheet rolls around the a-helix H1 to form
Table I
Data Collection and Refinement Statistics
Structure




Unit cell parameters 58.07 ; 72.74 ; 130.59 
Resolution 30.0–2.20 
No. of measured reflections 204,811









r.m.s.d. bond lengths 0.024 
r.m.s.d. bond angles 1.728
Subunits in asymmetric unit 1 1 1
No. of atoms (protein/water) 2019/130
Average B factors (protein/water) 46.7 2/50.7 2
Ramachandran allowed region 99.8%
Ramachandran disallowed region 0.4%
Values in parentheses are for the highest resolution shell of 2.32–2.20 Å.
aRmerge 5 ShSi|I(h)i 2 <I(h)>|/ShSiI(h)i, where I(h) is the intensity of reflection h, Sh
is the sum over all reflections, and Si is the sum over imeasurements of reflection h.
bR 5 ShkFobs(h)| 2 |Fcalc(h)k/Sh|Fobs(h)|, where F(h) is the structure factor of
reflection h. Rfree was calculated using 5% data excluded from refinement, and Rwork
using the other 95% data.
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Figure 1
Structure FAF1 UBX in complex with p97/VCP N domain. A: Overall structure of the complex between FAF1 UBX and p97/VCP N domain. B:
Closeup view of the binding interface. Several key residues are shown and the dashed line indicates a hydrogen bond. Transparent surface is
presented for p97/VCP N domain. C: Sequence alignment of UBX domains from various proteins. These UBX domains have been experimentally
shown to bind to p97/VCP N domain. Alignment was carried out by ClustalX20 and edited by Jalview.21 Blue shading represents the conservation.
The red triangle is for the residues in the binding interface and the blue circle for the residues forming the hydrophobic core of the fold.
Figure 2
FcisP touch-turn. A: Conformational change of the FcisP touch-turn, or S3/S4 loop. The ‘‘unbound’’ is from the our recent crystal structure of free
FAF1 UBX and the ‘‘bound’’ is the current structure of FAF1 UBX in complex with p97/VCP N domain. B: FcisP touch-turn, a rare case of an
open b-turn, formed by the four residues TFPR (residues 618–621). The dashed line represents the distance between Cai and Cai13.
the well-known b-grasp fold, as previously shown in its
NMR and crystal structures.8,10
It should be noted that the cis peptide between F619
and P620 of FAF1 UBX was observed for the first time in
our recently reported 2.9 Å crystal structure of FAF1
UBX alone10 and is confirmed by the high-resolution
electron density of the current 2.2 Å structure (Fig. 2). In
the previous NMR structures of UBX domains from p47
and FAF1 and the crystal structure of p47 UBX domain in
complex with p97/VCP ND1, the same peptide bond was
described commonly as trans.6,8,9 This point should be
emphasized because the conserved FcisP touch-turn motif
containing these two residues is a signature of p97/VCP-
binding UBX domains and plays a critical role in their
binding. It is also noteworthy that the FcisP touch-turn
motif in the S3/S4 loop clearly shows the characteristics of
a cis-Pro touch-turn, a rare case of an open b-turn. The
distance between Cai and Cai13 and dihedral angles u
and w of the F619 match very well with the defined values
of the cis-Pro touch-turn; the distance is 4.05 Å, which is
the range of the defined 4–5 Å, and the dihedral angles are
(146, 165) for F619 which fall into the defined (160,
160) region [Fig. 2(B)].22 Therefore, our finding of the
conserved FcisP touch-turn motif in UBX domain from its
recently reported crystal structure is further validated by
the current high-resolution structure in complex with p97/
VCP N domain.
The overall structure of p97/VCP N domain has two
characteristic subdomains (Nn subdomain of residues
25–106 and Nc of residues 112–186) forming a dumb-
bell-shape as previously observed [Fig. 1(A)].2 The main
b-sheet of FAF1 UBX domain faces one side of the
dumbbell-shaped p97/VCP N domain and the entire bur-
ied surface area covers about 1680 Å2 which is in the
typical range for protein–protein interactions.23 Between
the two subdomains of p97/VCP N domain is formed a
cleft into which FcisP touch-turn of FAF1 UBX is
inserted [Fig. 1(A)]. The side chain phenyl ring of F619
on the turn is deeply inserted into the cleft and makes
hydrophobic contacts with three residues (D35, V38, and
L72) of p97/VCP N domain. Another phenylalanine F645
on the strand S5 makes hydrophobic contacts through
stacking with Y143 at the bottom of the cleft. Surrounding
those two phenylalanines (F619 and F645), several hydro-
philic residues, including R579, K614, R621, and E647, form
hydrogen bonds to residues of p97/VCP near the cleft. The
two arginine residues, R579 and R621, that flank phenylal-
anine residues F619 and F645 together with cis-P620 line
up and insert into the cleft [Fig. 1(B)]. These five residues
including cis-P620 are highly conserved among the UBX-
containing proteins with experimentally shown binding ac-
tivity toward p97/VCP N domain [Fig. 1(C)]. This struc-
tural observation, together with the sequence conservation,
implies that the sequence motif composed of R579-
F619cisP620R621/N-F645/L/I/V, must be a signature of the
p97/VCP-binding activity of UBX domains.
To assess the contributions of these conserved residues
in the motif to the binding activity, we prepared four
single-point mutants (R579A, F619S, R621A, and F645S)
and two double-point mutants (F619S-R621A and
F619S-F645S). Isothermal calorimetric titration was car-
ried out with the purified proteins p97/VCP N domain
and these FAF1 UBX mutants or the wild type (Sup-
porting Information Fig. S1). The binding stoichiometry
was determined to be 1 (measured 1.06) indicating that
FAF1 UBX and p97/VCP N domain binds in a 1:1 ratio.
The dissociation constant, Kd, for the wild type FAF1
UBX was measured to be 11.2 lM. The single mutations
of R579A, F619S, R621A, or F645S increased Kd by an
order of magnitude, whereas the double mutations of
F619S-R621A or F619S-F645S by two orders of magni-
tude (Supporting Information Table S1). Among these
four residues, mutation of F619 exerted the strongest
effect. It is also notable that any single-point mutation is
not enough to abolish the interaction. The double-point
mutants (F619S-R621A and F619S-F645S) show 95–237
times greater Kd than the wild type and they seem to
have lost a greater part of the binding activity. Conclu-
sively, the conserved interface residues of R579-
F619cisP620R621/N-F645/L/I/V motif of FAF1 UBX domain
are important for its binding activity, as confirmed by
isothermal calorimetric titrations and as expected from
the crystal structure.
Conformational change in FcisP touch-turn
motif of UBX domain
The p97/VCP N domain bound to FAF1 UBX in our
crystal structure does not show any noticeable structural
difference from its free state observed in the crystal struc-
ture of ND1, Ref. 2, (PDB ID 1E32) with the an r.m.s.
deviation of 0.7 Å for the superposed Ca atoms of resi-
dues 24–191. It implies that the p97/VCP N domain is
rigid enough not to undergo any significant conforma-
tional change upon binding to FAF1 UBX domain. In
contrast, the FAF1 UBX bound to p97/VCP N domain
shows an important structural difference in its FcisP
touch-turn motif (or S3/S4 loop region, residues 618–
621) compared with its unbound state that was recently
observed in our recently reported crystal structure of
FAF1 UBX alone.10 Upon binding to p97/VCP N do-
main, the Ca atoms of residues F619 and P620 move by
about 118 in angle and about 2 Å in distance toward the
cleft in the p97/VCP N domain [Fig. 2(A)]. Interestingly,
the side chain phenyl ring of F619 partly stacks over P620
in the unbound state, whereas it swings out in the bound
state toward the cleft in p97/VCP N domain and forms
hydrophobic interactions with D35, V38, and L72 in the
cleft [Fig. 2(A)]. These structural differences of FAF1
UBX between its unbound and bound states imply that
its binding to p97/VCP N domain induces a conforma-
tional change in the region of FcisP touch-turn motif,
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resulting in insertion of the turn into the cleft in p97/
VCP N domain. This kind of conformational change was
not previously described for the UBX domain of p47,
another p97/VCP-binding UBX protein, whose structure
was determined in its unbound state using NMR spec-
troscopy6 and in a complex with p97/VCP ND1 using
X-ray crystallography.9
It is noteworthy that the binding stoichiometry of the
FAF1-p97/VCP complex is an open question. Our crystal
structure and the isothermal calorimetric titration data
indicate that FAF1 UBX domain binds to p97/VCP N do-
main in a 1:1 ratio. However, it does not necessarily mean
that the full-length FAF1 and p97/VCP forms a 6:6 com-
plex. This notion is corroborated by the fact that p47 UBX
domain can bind to p97/VCP in a 6:6 ratio but the full-
length p47 binds to p97/VCP to form a 3:6 complex.24,25
In summary, we determined the crystal structure of
FAF1 UBX domain in complex with p97/VCP N domain.
It revealed that a significant conformational change of
FAF1 UBX domain is induced around the conserved
FcisP touch-turn upon its insertion into the cleft of p97/
VCP N domain for binding. The FcisP touch-turn moves
by about 118 (2 Å in distance) toward the cleft, with
the side-chain phenyl ring of the phenylalanine residue
swinging out and getting deep into the cleft. In addition,
mutational studies, together with the structural observa-
tions, indicate that five highly conserved residues, R579-
F619cisP620R621/N-F645/L/I/V, are important for the bind-
ing of FAF1 UBX domain to p97/VCP N domain.
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Helical Repeat Structure of Apoptosis Inhibitor 5 Reveals
Protein-Protein Interaction Modules*□S
Received for publication, October 27, 2011, and in revised form, February 9, 2012 Published, JBC Papers in Press, February 12, 2012, DOI 10.1074/jbc.M111.317594
Byeong-Gu Han‡§1, Kyoung Hoon Kim¶1, Sang Jae Lee‡1, Kyung-Chae Jeong‡, Jea-Won Cho‡, Kyung Hee Noh,
Tae Woo Kim, Soon-Jong Kim**, Hye-Jin Yoon¶, Se Won Suh¶, Sangho Lee§, and Byung Il Lee‡2
From the ‡Biomolecular Function Research Branch, Division of Convergence Technology, Research Institute, National Cancer
Center, Goyang, Gyeonggi 410-769, Korea, the ¶Department of Chemistry and Department of Biophysics and Chemical Biology,
College of Natural Sciences, Seoul National University, Seoul 151-747, Korea, the Department of Biomedical Sciences, Graduate School
of Medicine, Korea University, Seoul 136-701, Korea, the **Department of Chemistry, Mokpo National University, Chonnam 534-729,
Korea, and the §Department of Biological Sciences, Sungkyunkwan University, Suwon, Gyeonggi 440-746, Korea
Background: Up-regulated in various cancers, API5 prevents apoptosis under growth factor deprivation.
Results:We have determined the crystal structure of API5 with the HEAT and ARM repeat and show that Lys-251 acetylation
is important for its function.
Conclusion: API5 likely serves as a scaffold for multiprotein complex with its cellular function regulated by lysine acetylation.
Significance: Structural basis of API5 function is important in targeting anti-apoptosis.
Apoptosis inhibitor 5 (API5) is an anti-apoptotic protein that
is up-regulated in various cancer cells.Here,wepresent the crys-
tal structure of human API5. API5 exhibits an elongated all
-helical structure. TheN-terminal half of API5 is similar to the
HEAT repeat and the C-terminal half is similar to the ARM
(Armadillo-like) repeat. HEAT and ARM repeats have been
implicated in protein-protein interactions, suggesting that the
cellular roles of API5 may be to mediate protein-protein inter-
actions. Various components of multiprotein complexes have
been identified asAPI5-interacting protein partners, suggesting
that API5 may act as a scaffold for multiprotein complexes.
API5 exists as a monomer, and the functionally important hep-
tad leucine repeat does not exhibit the predicted a dimeric leu-
cine zipper. Additionally, Lys-251, which can be acetylated in
cells, plays important roles in the inhibition of apoptosis under
serumdeprivation conditions. The acetylation of this lysine also
affects the stability of API5 in cells.
Apoptosis, a programmed cell death process, plays impor-
tant roles in sculpting the developing organism and in main-
taining cell number homeostasis (1, 2). It is also critical for
effective cancer chemotherapy (3). Twomain pathways of apo-
ptosis have been studied extensively. The extrinsic pathway is
mediated by interactions between the death receptors and
death ligands. This induces the formation of the death-induc-
ing signaling complex and caspase-8 (4). The intrinsic pathway,
which is triggered by radiation, drugs, reactive oxygen species,
and radicals, beginswith the release of cytochrome c frommito-
chondria, which ultimately activates caspase-9 (4, 5). These
pathways converge downstream, as both caspase-8 and
caspase-9 activate caspase-3 (4, 6). Activated caspases cleave
specific target proteins, such as protein kinases, cytoskeletal
proteins, and DNA repair proteins, initiating apoptosis (6, 7).
The characteristic markers of apoptosis include cell and
nuclear shrinkage, DNA cleavage into nucleosomal fragments,
chromatin aggregation, and apoptotic body formation (8).
Because the precisely regulated events of apoptotic cell death
are frequently altered in cancers, proteins in the apoptotic path-
way can represent good targets for anti-cancer drugs (9).
Inhibitor of apoptosis (IAP)3 family proteins are negative
regulators of apoptosis and were characterized originally as
physical inhibitors of caspases (10). Eight IAP proteins have
been identified, and each of these proteins contains an 70-
amino acid BIR (baculovirus IAP repeat) domain that mediates
protein recognition and interactions (11). Some IAPs include
additional domains, such as a RING (really interesting new
gene) domain, UBA (ubiquitin-associated domain), or CARD
(caspase recruitment domain). Anti-cancer drugs that target
IAPs bymimicking theN-terminal IAP bindingmotif (Ala-Val-
Pro-Ile) of Smac are currently in clinical trials for some solid
tumors and lymphomas (12).
API5 (apoptosis inhibitor 5), also known as AAC-11 protein
(anti-apoptosis clone 11), FIF (fibroblast growth factor 2-inter-
acting factor), and MIG8 (cell migration-inducing gene 8), is a
relatively poorly studied apoptosis-inhibiting nuclear protein
that does not contain a baculovirus IAP repeat domain. The
API5 gene has been found in animals, protists, and plants (13).
The expression of API5 prevents apoptosis following growth
factor deprivation, and this protein is up-regulated in various
* This work was supported by the Basic Science Research Program through
the National Research Foundation of Korea funded by Ministry of Educa-
tion, Science, and Technology Grant 2010-0020993 (to B. I. L.).
The atomic coordinates and structure factors (codes 3U0R and 3V6A) have been
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cancer cells (14–19).Non-small cell lung cancer patientswhose
cancers express API5 have a poorer prognosis than patients
with non-API5-expressing cancers, and overexpression ofAPI5
promotes the invasion and inhibits apoptosis in cervical cancer
cells (15, 17, 20). It has been suggested that API5 suppresses
E2F1 transcription factor-induced apoptosis (21). A recent
study also suggested that API5 is phosphorylated by PIM2
kinase and inhibits apoptosis in hepatocellular carcinoma cells
through NF-B (nuclear factor-B) (22). Various API5 interac-
tion partners have been identified. API5 interacts with high
molecular mass forms of fibroblast growth factor 2 (FGF-2),
which are involved in cell proliferation and tumorigenesis (16).
API5 also binds to and regulates Acinus, a protein involved in
chromatin condensation and DNA fragmentation during apo-
ptosis (23). Moreover, the inhibition of API5 increases anti-
cancer drug sensitivity in various cancer cells (23). Recently, the
chromatin remodeling enzyme ALC1 (amplified in liver cancer
1) and twoDEAD box RNAhelicases were identified as binding
partners of API5 (13, 24). From these data, API5 has been
regarded as a putative metastatic oncogene and therefore rep-
resents a therapeutic target for cancer treatment (23). The
rational design of inhibitors of API5 will be aided by determi-
nation of its three-dimensional structure. Additionally, the lack
of sequence similarity between API5 and other known proteins
has made it difficult to predict its molecular function. There-
fore, structural information about API5 will be helpful in eluci-
dating its molecular function.
We determined the crystal structure of human API5 to elu-
cidate the molecular basis of its anti-apoptotic function. API5
contains a multiple helices, forming HEAT and ARM (Arma-
dillo)-like repeats, which are known to function in protein-pro-
tein interactions. This study thus reveals that API5 acts as a
mediator of protein interactions.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—The human API5 gene
(full-length (1–504), API5C (1–454)) was amplified by PCR
and cloned into pET28b() (Novagen) using NdeI and NotI
restriction sites. This construction adds a 21-residue tag
including His6 to the N-terminal of the recombinant protein,
facilitating protein purification. The mutants (K251Q, K251R,
and K251A) of the API5 gene were prepared by QuikChange
site-directed mutagenesis method using the wild type plasmid
as the PCR template. The wild type and mutant proteins were
overexpressed in Escherichia coli Rosetta2(DE3) cells (Nova-
gen). The cells were grown at 37 °C in 4 liters of Terrific Broth
medium to an A600 of 0.7, and expression of the recombinant
protein was induced with 0.5 mM isopropyl -D-thiogalactopy-
ranoside at 37 °C. The cells were grown at 37 °C for 16 h after
isopropyl -D-thiogalactopyranoside induction and were har-
vested by centrifugation at 3000  g for 10 min at 4 °C. The cell
pellet was suspended in ice-cold lysis buffer (25 mM Tris-HCl,
pH 7.4, 138 mM NaCl, 2 mM KCl, 10% (v/v) glycerol, 1 mM
phenylmethylsulfonyl fluoride, and 0.8 M lysozyme) and
homogenized by sonication. The first purification step utilized
a Ni2 nitrilotriacetic acid column (Qiagen) for affinity purifi-
cation via the N-terminal His6 tag. The eluent was pooled and
concentrated. The protein sample was diluted 10-fold with
buffer (50 mM Tris-HCl, pH 8.0, 80 mM NaCl, and 1 mM DTT).
Further purification was conducted using a HiTrap Q ion
exchange chromatography column (GE Healthcare) equili-
brated with buffer (50mMTris-HCl, pH 8.0, 80mMNaCl, and 1
mM DTT). The protein was eluted using a linear gradient of
0–1.0 M sodium chloride in the same buffer. The final purifica-
tion step was gel filtration on a HiLoad 16/60 Superdex 200
prep-grade column (GE Healthcare) equilibrated with buffer
containing 20 mM sodium citrate, pH 5.5, 200 mM NaCl,
and 1mMDTT. The purified API5 protein was concentrated to
20 mg/ml using an YM10 membrane (Millipore). Human
-thrombin (Enzyme Research Laboratories) or porcine tryp-
sin (Promega) was used to remove the fusion tag or to achieve
limited proteolysis, respectively.
Crystallization, X-ray Data Collection, and Structure
Determination—The best crystals were obtained with a reser-
voir solution of 10%PEG6000 and 100mMbicine, pH 9.0, using
the API5C protein. For x-ray diffraction data collection, crys-
tals were transferred to a cryoprotectant solution (10% PEG
6000, 100 mM Bis-Tris, pH 6.0, and 30% ethylene glycol) and
mounted on nylon loops. Data of API5Cs (wild type and
K251Qmutant) were collected using an ADSC Quantum CCD
detector at the 4A and 6C experimental stations, Pohang Light
Source, Korea and an ADSC Quantum 4 CCD detector at the
BL-1A experimental station, Photon Factory, Japan, respec-
tively. Intensity data were processed and scaled using the pro-
gram HKL2000 (25). Selenium sites were located with SOLVE
(26) using two MAD data sets. Initial phases were improved
using the program RESOLVE (26). Manual model building was
performed using the program COOT (27), and the model was
refined with the program PHENIX (28) and Refmac (29),
including bulk solvent correction. As the test data for the cal-
culation of Rfree, 5% of the data were randomly set aside (30).
The refined models were evaluated using MolProbity (31).
Analytical Ultracentrifugation—Equilibrium sedimentation
experiments were performed using a Beckman ProteomeLab
XL-A analytical ultracentrifuge in 20mM sodium citrate buffer,
pH 5.5, containing 200mMNaCl, at 20 °C. Absorbances of API5
samples were measured at 235, 240, and 280 nm using a two-
sector cell at two different speeds (12,000 and 16,000 rpm) and
two different concentrations (4.90 and 9.80 M) with a loading
volume of 180 l. The calculated partial specific volumes at
20 °Cwere 0.7452 and 0.7416 cm3/g forAPI5Cand full-length
API5, respectively. The buffer density was 1.01424 g/cm3. For
mathematical modeling using non-linear least-squares curve
fitting, the fitting function for homogeneous models was used,
as described elsewhere (32). The model was selected by exam-
ining the weighted sum or square values and weighted root
mean square deviation (r.m.s.d.) values.
Cell Viability Test—Jurkat cells were grown in RPMI 1640
media supplemented with 10% fetal bovine serum (WelGENE).
Transient transfectionwas performedwith Lipofectamine LTX
and Plus Reagent (Invitrogen) according to the manufacturer’s
instructions. Briefly, 2.3  105 Jurkat cells were seeded in the
medium onto a 24-well plate. After 1 h, the cells in each well
were transfected with 0.6 g of each DNA construct (full-
length API5 wild type, K251R, K251Q, and K251A, respec-
tively). After 3 h, the serum-free medium was exchanged with
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RPMI1640 medium containing 10% fetal bovine serum to sta-
bilize the transfected cells. After an additional 12-h incubation,
the culture medium was exchanged with serum-free RPMI
1640 to perform a starvation test. Following a 48-h incubation,
the cell viability in each well was determined using a Presto cell
proliferation assay kit (Invitrogen) according to the manufac-
turer’s instructions.
Immunoprecipitation andWestern Blotting—Tomonitor the
oligomerization state of API5 in cells, full-length HA-API5 and
3FLAG-API5 were co-transfected into HeLa cells and immu-
noprecipitated. Whole cell lysates prepared in lysis buffer (50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate), were
used for immunoprecipitation. Each lysate was mixed with a
binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1
mM EDTA) supplemented with protease inhibitor cocktails
(RocheApplied Science). Themixture was incubated overnight
at 4 °Cwith antibodies (diluted 1:100). A/G-agarose beads were
then added, incubated at 4 °C for 3 h, and washed four times
with the binding buffer. The immune complex was released
from the beads by boiling in sample buffer andwas visualized by
Western blotting.Western blottingwas carried out using estab-
lished protocols. The primary antibodies used were anti-HA
(Santa Cruz Biotechnology), anti-FLAG (Cell Signaling Tech-
nologies), and anti--actin (Abcam).
To test protein stability in cells, full-length wild type API5 or
mutants API5 (K251R and K251Q) was transfected into HeLa
cells. At 22 h after transfection, the cells were treated with 10
g/ml of cycloheximide for 4 h. Then, the cells were collected,
and protein levels were analyzed by Western blotting. For the
deacetylase inhibition experiments, suberoylanilide hydroxamic
acid was pretreated for 20 h to the wild type API5-transfected
HeLa cells before cycloheximide treatment.
RESULTS
Structure Determination and Overall Structure—We ob-
tained crystals of full-length and trypsin-treated API5. How-
ever, only the crystals of trypsin-treated API5 were suitable
for structure determination. From N-terminal amino acid
sequencing and MALDI-TOF analysis, we found that the
N-terminal fusion tag and 50 amino acid residues at the
C-terminal of recombinant API5 were removed by trypsin and
that the trypsin-treated form of API5 corresponded to residues
1–454. The crystal structure of API5C was solved by multi-
wavelength anomalous dispersion and refined to 2.50 and 2.60
Å resolution for wild type and K251Q (acetylation mimic)
mutant structures, respectively. The refined models of wild
type and K251Qmutant exhibited working and free R-values of
21.6 and 24.2%, and 21.3 and 25.0%, respectively, with good
stereochemistry (Table 1). One subunit of API5C was found
to be present in the asymmetric unit of the crystal. The struc-
tures of wild type and K251Qmutant are highly similar to each
other, with an r.m.s.d. of 0.32 Å for 424 C atom pairs (supple-
mental Fig. S1).
The API5Cmonomer presented an elongated, all -helical
repeat structure, forming a right-handed superhelix with
approximate dimensions of 100  35  50 Å (Fig. 1A). It con-
sisted of 19 -helices (1–19) and two 310 helices. Each helix
was observed to be paired with its neighboring helix to form an
antiparallel helix pair. Residues 277–278, 322–335, 365–366,
430–431, and 447–454, as well as the four extra N-terminal
residues (Gly-Ser-His-Met), artificially added by cloning into
pET-28b, were disordered in the crystal. The C-terminal region
of API5 (residues 455–504), which contains a nuclear localiza-
tion signal (Fig. 2) between residues 454–475 and is predicted
to be disordered by IUPRED (33), was readily removed by tryp-
sin. Additionally, an electron density map calculated using low
resolution (6 Å) x-ray diffraction data from full-length API5
did not show this C-terminal region, supporting its hypothe-
sized flexibility (data not shown). Several positively charged
patches were found on the concave surface of the API5C pro-
tein, whereas mainly negatively charged residues were posi-
tioned on the convex side (Fig. 1B). The positively or negatively
charged patches were well conserved in various species (Fig.
1C). Basic patches were also found near the putative leucine
zipper region (heptad leucine repeat). However, a basic DNA
binding region typically followed by a leucine zipper of other
leucine repeat proteins, was not found to be present in API5
(Fig. 2).
Searches using the DALI server were carried out to identify
structurally similar proteins (34). Because the structure of
API5C can be divided into two regions, DALI searches were
performed separately for the N-terminal half (1-11) and the
C-terminal half (12–19). The N-terminal half of API5 struc-
turally aligns with theHEAT repeat regions of importin (PDB
code 1O6P, Z-score  13.1; r.m.s.d., 4.7 Å for 190 structurally
aligned residues), the TOG2 domain ofMsps (PDB code 2QK2,
Z-score  12.2; r.m.s.d.  4.5 Å for 176 structurally aligned
residues), and protein phosphatase 2A (PDB code 2C5W,
Z-score  11.8, r.m.s.d.  1.8 Å for 87 structurally aligned res-
idues). Although the sequence identities between the structur-
ally aligned regions and API5 were only 10–12%, the overall
folds were quite similar. The C-terminal half of API5 is struc-
turally similar to the core region of the U-box-containing ubiq-
uitin ligase E4 protein Ufd2p (PDB code 2QIZ, residues 461–
747). The Z-score and r.m.s.d. values for the aligned 195 amino
acid pairs were 8.3 and 4.4 Å, respectively. The amino acid
sequences were also quite different between API5 and Ufd2p
(lower than 11% sequence identity), although the three-dimen-
sional structureswere quite similar, including the characteristic
long helix pair (18-19). The second most similar protein to
the C-terminal half of API5 was p120 catenin (PDB code 3L6Y,
Z-score  7.7, r.m.s.d.  3.3 Å for the aligned 152 amino acid
pairs). Ufd2p and p120 catenin have been classified as ARM-
like repeat proteins. These results indicate that the N-terminal
half of API5 adopts the characteristic HEAT repeat structure,
which is composed of pairs of antiparallel helices, whereas the
C-terminal half of API5 shows an ARM-like repeat structure.
Superposition of API5 and the structurally similar protein is
shown in Fig. 3. The interhelix turns between antiparallel heli-
ces are relatively short (between two and four residues) in the
HEAT repeats of API5, resulting in a tight fold of the repeat
structure, whereas the turns in the ARM-like repeat regions are
longer (6 to 22 residues) (Fig. 2).
The amino acid sequence of API5 contains an LxxLL motif
(16). The LxxLLmotif forms a short amphipathic -helix and is
Structure of Apoptosis Inhibitor 5
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usually found in nuclear receptor-cofactor interaction regions
(35, 36). The LxxLL motif in API5 is positioned in 6 (Figs. 1A,
2, 4A). However, the three leucine residues in this motif are not
located on the surface of the protein and likely do not play any
role in protein-protein interactions. Instead, because they are
located in the interior of the protein, theymay contribute to the
stability of the HEAT repeat by forming hydrophobic interac-
tions with neighboring -helices. Leu-102 interacts with Ala-
120, Ile-124 of 7, and Leu-86 of 5. Leu-105 and Leu-106
interact with Val-117 and Phe-114 of 7, respectively (Fig. 4A).
This finding is consistent with a previous report indicating that
the replacement of these conserved leucine residues does not
abolish FGF-2 binding (16).
Assessment of API5 Oligomerization and Heptad Leucine
Repeat Region—The heptad repeat of leucine residues between
residues 370 and 391 in API5 has been predicted to be a leucine
zipper without a basic DNA-binding region (14). Therefore, it
has been suggested that API5 may form a dimer in solution.
However, the crystal structure of API5C indicates that API5 is
monomeric and that the putative leucine zipper (18) does not
interact with the corresponding helix of another subunit.
Instead, it interacts with 19 of the same subunit (Figs. 1A and
4B). Two sets of low resolution data were collected from crys-
tals of full-length API5 (6 Å resolution) or API5C (4 Å
resolution) grown under different crystallization conditions.
Protein molecules positioned by the molecular replacement
method indicate that both API5 and API5C are monomeric
under different crystallization conditions (data not shown).
Because the oligomeric state of API5 in the crystal was found
to be different from the predicted dimeric state, the relevant
oligomeric state of API5 in solution was further investigated by
analytical ultracentrifugation (Fig. 5A). The estimated molecu-
lar mass (54,949 Da (234)) agreed with the calculated molec-
ular mass for an API5C monomer, including the fusion tag
(53,521 Da). The full-length API5 protein was also found to be
monomeric, indicating minimal effects of the C-terminal trun-
cation on the oligomeric structure of API5. The estimated
molecular mass of full-length API5 (60,129 Da (1,164))
agreed with the calculated molecular mass for the full-length
API5 monomer including the fusion tag (58,934 Da).
Additionally, we transiently expressed HA-tagged and
3FLAG-tagged full-length API5 in HeLa cells and performed
FIGURE 1. The overall structural representation of API5. A, the ribbon diagram of API5C reveals its elongated, all -helical structure. B, surface charge
properties of API5C. The concave region of API5 is highly positively charged, whereas the convex region is negatively charged. The acidic and basic residues
in the surface are denoted. Lys-251, shown using red dashed circles, is solvent-exposed, allowing access by acetyltransferases or deacetylases. C, surface
representation colored by amino acid sequence conservation. Surface conservation was generated using ConSurf (57).
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immunoprecipitation experiments (Fig. 5B). No interaction
was found between HA-tagged API5 and 3FLAG-tagged
API5. This result shows that API5 does not homodimerize in
cells. However, we cannot rule out the possibility that API5
heterodimerize with other leucine zipper-containing proteins
under specific cellular conditions. Taken together, we unex-
pectedly discovered that API5 is monomeric and that its
putative leucine zipper helix (18) does not participate in
dimerization. Three of the four leucine residues in the heptad
repeat (Leu-377, Leu-384, and Leu-391) exhibit hydrophobic
interactions with hydrophobic residues in 19; Leu-377 and
Leu-384 interact with Ile-425 and Ile-421, respectively, and
Leu-391 is close to Leu-415 (Fig. 4B). Leu-370 does not interact
with other residues.
Lysine Acetylation and Its Effect on Cancer Cells—A global
mass analysis showed that Lys-251 of API5 is acetylated in
cells (37). Amino acid sequence alignment showed that this
lysine residue is strictly conserved across a number of spe-
cies (Fig. 2). Lys-251 is positioned in a loop between 13 and
14, which is extended from the protein (Fig. 1B). This find-
ing suggests that acetyltransferases or deacetylases can easily
access this residue.
API5 plays important roles in the inhibition of cell death
under serum deprivation conditions (14, 15). Therefore, we
testedwhether lysine acetylation affected cell viability 48 h after
the transient transfection under serum deprivation conditions
(Fig. 6A). We made an acetylation-deficient, a constitutive
acetylation mimic, and an uncharged mutant (K251R, K251Q,
and K251A, respectively) (37, 38).Wild type API5 inhibited cell
death by serum starvation compared with untreated or control
vector-transfected cells. The K251R mutant exhibited even
higher cell viability. However, the K251Q mutant did not
inhibit apoptosis efficiently compared with the wild type API5
and the K251R mutant. The K251A mutant did not have anti-
apoptotic function. This result means that the inhibition of
apoptosis byAPI5 can be negatively regulated by Lys-251 acety-
lation. We tried to find the structural basis for anti-apoptotic
function by lysine acetylation from the structure of K251Q
mutant. However, no significant structural differences were
found (supplemental Fig. S1).
FIGURE 2. Amino acid sequence alignment of API5 homologs from different species. The LxxLL motif is marked with a black box. The conserved leucine
residues of the heptad leucine repeat are marked by blue circles, and the acetylation site Lys-251 is marked by a blue triangle. The LxxLL motif and nuclear
localization signal (NLS) sequence are marked. The amino acid sequence for isoform 2 of human API5, which was used in this study, is also denoted above the
sequence. The figure was prepared using ESPript.
FIGURE 3. The structural similarity between API5 and HEAT and ARM motif-containing proteins. A, the N-terminal half of API5 is structurally similar to
importin  (salmon). B, the C-terminal-half of API5 is structurally similar to the core domain of Ufd2p (yellow). Superimposed regions are indicated by dashed
boxes.
FIGURE 4. Detailed motif/domain structure of API5. A, LxxLL motif and interacting residues. The leucine residues interact with hydrophobic residues on the
adjacent helices and are involved in stabilization of the repeated structure. B, heptad leucine repeat region. 18 is covered by 19 from the same subunit and
does not form a typical leucine zipper. The leucine residues of the heptad repeat and hydrophobic residues on 19 are close to each other (shown in a stick
representation).
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We also tested whether lysine acetylation affected API5 pro-
tein stability. After 22 h of transfection, protein synthesis was
stopped by treatment with cycloheximide, and the protein level
was monitored by Western blot analysis after 4 h of treatment.
The K251Q mutant was more stable than the wild type API5
and the K251Rmutant (Fig. 6B). Similar results were also found
when deacetylase inhibitor suberoylanilide hydroxamic acid
was treated (Fig. 6C). Therefore, we conclude that the regula-
tion of API5 function by lysine acetylationmay occur via effects
on protein stability. However, we could not detect any ubiquiti-
nation of API5 at Lys-251, suggesting the proteasome-inde-
pendent degradation pathway (data not shown).
The cellular localization of API5 also was monitored to
determine whether lysine acetylation affected the nuclear
transport of API5. All of the wild type and mutants API5
(K251R and K251Q) were observed in the cell nuclei, implying
that lysine acetylation did not affect cellular localization (sup-
plemental Fig. S2). The analysis of the API5 and FGF-2 interac-
tion detected by in vitro immunoprecipitation method using
the purified recombinant API5 and FGF-2 did not show any
significant FGF-2 binding differences between wild type and
mutant API5s (supplemental Fig. S3).
DISCUSSION
In this study, we determined the crystal structure of human
API5 and found that API5 contains protein-protein interaction
modules, such as HEAT and ARM repeats (Fig. 1A). Different
types of helix repeat, includingHEAT,ARM, ankyrin, tetratrico
peptide, and leucine-rich variant repeats, have been found in
many proteins and have diverse functional roles in mediating
protein-protein interactions (39). The elongated structure of
API5 is well suited for interactions with multiple binding part-
ners, similar to the roles of other repeat proteins (40).
The structures of variousHEATandARMrepeat-containing
proteins in complexes with other proteins have been eluci-
dated. Ran-importin, protein phosphatase 2 holoenzyme, and
the Cand1-Cul1-Roc1 complex are good examples of HEAT
repeat complex structures (importin, theA subunit of protein
phosphatase 2 holoenzyme, and Cand1 are HEAT repeat-con-
taining proteins) (41–43). Several crystal structures of the
FIGURE 5. Oligomerization of API5. A, analytical ultracentrifugation analysis. Distributions of the residuals according to both a monomer (1, circle) and a
dimer (2, square) models. The random distributions of residuals for the monomer (1) model indicate that API5C exists as a homogeneous monomer in
solution. B, immunoprecipitation (IP) and Western blot (WB) analysis with anti-FLAG and anti-HA API5. No interaction was found between FLAG-API5 and
HA-API5, ruling out the possibility of API5 homodimerization.
FIGURE 6. Effects of API5 acetylation at Lys-251. Wild type API5, an acetylation-deficient mutant (K251R), a constitutive acetylation mimic mutant (K251Q),
and an uncharged mutant (K251A) were transiently expressed. A, effects on cell viability under conditions of serum deprivation. The K251Q and K251A mutants
do not inhibit apoptosis efficiently. B, effects of Lys-251 acetylation on protein stability. Cycloheximide (CHX) treatment was used to inhibit protein synthesis,
and Western blot (WB)/normalized densitiometry analysis was performed to monitor protein stability in cells. C, effects on protein stability when deacetylase
inhibitor, suberoylanilide hydroxamic acid (SAHA), was co-treated with cycloheximide to wild type API5-transfected cells.
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ARM repeat-containing protein (e.g. -catenin) in complex
with the interacting proteins have been determined (44–47). In
many curved HEAT repeat proteins, protein-protein interac-
tions are mediated by the concave surface of the protein,
regardless of the surface charge distribution, and the protein-
protein interaction surface involving the ARM repeat proteins
usually span the entire range of the repeat. The charged con-
cave or convex side of the API5 is well conserved across a num-
ber of species. This suggests that binding partners can bind to
these regions.
It has been reported that high molecular mass FGF-2 inter-
acts with API5 in the nucleus, and immunoprecipitation results
suggest that two separate regions corresponding to three heli-
ces (6 and 15–16) of API5 are important for FGF-2 binding
(16). The 6 is exposed to the convex surface of API5, and
15-16 are exposed on both the concave and convex surfaces.
Analyses of surface properties indicated that the convex side of
API5 is highly negatively charged, whereas FGF-2 is highly pos-
itively charged (Fig. 1B). Although hydrophobic interactions
may also be important for binding, we predict that the posi-
tively charged high molecular mass FGF-2 likely binds to the
negatively charged convex surface of API5, as determined from
previous immunoprecipitation results and surface electrostatic
potential (16).
It has been reported thatAPI5 binds toAcinus and protects it
from cleavage by caspase-3, resulting in an inhibition of apo-
ptosis (23). Acinus has been identified as a component of an
ASAP (apoptosis and splicing-associated protein) complex and
an exon junction complex (EJC) (48, 49). API5 and Acinus
interact with each other through the heptad leucine repeat
region of API5, which seems to be important for API5 function
and may therefore represent a potential therapeutic target
for anti-cancer drugs (23). Mutation of leucine residues (Leu-
384 and Leu-391) in the heptad leucine repeat region abrogates
the anti-apoptotic effects of API5 (14, 23). Because Leu-384 and
Leu-391 contribute to hydrophobic interactions with other
hydrophobic residues in 19, mutation of these residues might
cause a distortion of the local structure of API5, thus affecting
protein-protein interactions, rather than inhibiting the
dimerization. Because API5 is monomeric and the heptad leu-
cine repeat of API5 is structurally distinct from that of other
leucine zippers, API5 provides a unique opportunity for anti-
cancer drug discovery through targeting of this region. How-
ever, further studies and target validation will be required to
develop API5-targeted inhibitors.
It is known thatN-acetylation at lysine residues affectsDNA
binding, protein-protein interaction, cellular localization, ubiq-
uitination, phosphorylation, and protein stability (50). A global
analysis of lysine acetylation using high resolution mass spec-
trometry showed that Lys-251 of API5 is acetylated (37). Our
data clearly showed that lysine acetylation impacts cell survival
under serum deprivation conditions, suggesting an inhibition
of function. Therefore, we conclude that API5 function is neg-
atively regulated by acetylation at Lys-251. Inhibition of func-
tion via acetylation has also been found in HSP90 and 14-3-3
proteins (37, 38). We determined that lysine acetylation affects
API5 protein stability, which has been found for p53 as well
(51). However, we could not detect ubiquitination of API5, and
a detailed mechanism for degradation of API5 has not yet been
established. We predict that API5 may be readily acetylated by
an acetyltransferase(s) after protein synthesis and that API5
exists in an inactive and stable state in cells until certain
deacetylases can activate API5 through deacetylation. How-
ever, activated API5 appears to be unstable and easily degraded
in cells. Although the acetyltrasferases or deacetylases that act
onAPI5 have not yet been identified, these enzymes are likely to
be important regulatory factors for the function of API5. Addi-
tionally, we predict that certain histone deacetylase inhibitors
may also be effective in regulating API5 function.We could not
found any significant differences in API5-FGF-2 interaction
and cellular localization from the lysine acetylation mimic/de-
ficient mutants. However, it is still possible that lysine acetyla-
tion of API5 will affect protein-protein interactions between
API5 and other API5 interacting partners to induce anti-apo-
ptosis function. We can easily predict that lysine acetylation
can inhibit the binding of API5 to its binding partners for its
proper function. However, it is also quite likely that lysine
acetylated API5 can be recognized by new binding partners,
such as bromodomain containing proteins, resulting in a nega-
tive regulation of apoptosis (52). Hence, further investigations
are needed to elucidate the detailed mechanism for functional
regulation by lysine acetylation.
A recent report suggested that the rice API5 homolog inter-
acts with two DEAD-box RNA helicases AIP1/2 (API5-inter-
acting protein 1/2), thereby regulating programmed cell death
in the tapetum during the development of male gametophytes
(13). The human homolog of rice AIP1/2 is theATP-dependent
RNA helicases UAP56. This protein is involved in pre-mRNA
splicing andmRNA nuclear export (53). Interestingly, hUAP56
is a component of large protein complexes, such as the EJC or
TREX (Transcription-export) complex (54, 55). Particularly,
Acinus, another API5 binding protein, is also a component of
EJC complex, implying the functional link between API5 and
EJC complex. Another study showed that API5 interacts with
the chromatin-remodeling enzyme ALC1 (also known as
CHD1L), which is a member of the SNF2 family containing a
DEAHbox helicase domain (24). ALC1 plays important roles in
promoting cell proliferation and inhibits apoptosis in hepato-
cellular carcinoma (56). ALC1 also has been shown to interact
with various DNA repair proteins such as DNA-PKCs, Ku,
PARP1 (Poly [ADP-ribose] polymerase 1), XRCC (X-ray repair
cross-complementing protein), andAPLF (Aprataxin PNK-like
factor) as well as API5 (24), implying that API5 may also medi-
ate protein-protein interactions in DNA damage response pro-
tein complexes. Taken together, the interactions between API5
and EJC component proteins and chromatin-remodeling
enzyme such as ALC1 suggest the possible roles of API5 at a
transcriptional level.
In conclusion, the protein structure obtained in this study
reveals that API5 possesses protein-protein interaction mod-
ules that likely mediate interactions with partners such as high
molecular mass FGF-2, Acinus, AIP1/2, and ALC1. These
interacting proteins are usually components of multiprotein
complexes. Therefore, API5 may serve as a scaffold for multi-
protein complexes, and the identification of interacting protein
partners will help to illuminate the functional roles of API5.
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Furthermore, since we show that the API5 function is regulated
by lysine acetylation, identifying the lysine acetyltransferases
and deacetylases that act on API5 should also yield a better
understanding of the mechanisms that regulate API5 function.
Acknowledgments—We thank the staff at the Pohang Light Source
(beamlines 4A and 6C) and the Photon Factory (BL-1A) for assistance
with synchrotron data collection.
REFERENCES
1. Meier, P., Finch, A., and Evan, G. (2000) Apoptosis in development. Na-
ture 407, 796–801
2. Danial, N. N., and Korsmeyer, S. J. (2004) Cell death: Critical control
points. Cell 116, 205–219
3. Igney, F. H., and Krammer, P. H. (2002) Death and anti-death: Tumor
resistance to apoptosis. Nat. Rev. Cancer 2, 277–288
4. Yang, S. Y., Sales, K. M., Fuller, B., Seifalian, A. M., and Winslet, M. C.
(2009) Apoptosis and colorectal cancer: Implications for therapy. Trends
Mol. Med. 15, 225–233
5. Altieri, D. C. (2010) Survivin and IAP proteins in cell death mechanisms.
Biochem. J. 430, 199–205
6. Ghobrial, I. M., Witzig, T. E., and Adjei, A. A. (2005) Targeting apoptosis
pathways in cancer therapy. CA Cancer J. Clin. 55, 178–194
7. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thorn-
berry, N. A., Wong, W. W., and Yuan, J. (1996) Human ICE/CED-3 pro-
tease nomenclature. Cell 87, 171
8. Wyllie, A. H., Kerr, J. F., and Currie, A. R. (1980) Cell death: The signifi-
cance of apoptosis. Int. Rev. Cytol. 68, 251–306
9. Kasibhatla, S., and Tseng, B. (2003) Why target apoptosis in cancer treat-
ment?Mol. Cancer Ther. 2, 573–580
10. Salvesen,G. S., andDuckett, C. S. (2002) IAPproteins: Blocking the road to
death’s door. Nat. Rev. Mol. Cell Biol. 3, 401–410
11. Srinivasula, S. M., and Ashwell, J. D. (2008) IAPs: What’s in a name?Mol.
Cell 30, 123–135
12. Gyrd-Hansen, M., and Meier, P. (2010) IAPs: From caspase inhibitors to
modulators of NF-B, inflammation, and cancer. Nat. Rev. Cancer 10,
561–574
13. Li, X., Gao, X., Wei, Y., Deng, L., Ouyang, Y., Chen, G., Li, X., Zhang, Q.,
and Wu, C. (2011) Rice APOPTOSIS INHIBITOR5 coupled with two
DEAD-box adenosine 5	-triphosphate-dependent RNA helicases regu-
lates tapetum degeneration. Plant Cell 23, 1416–1434
14. Tewari, M., Yu, M., Ross, B., Dean, C., Giordano, A., and Rubin, R. (1997)
AAC-11, a novel cDNA that inhibits apoptosis after growth factor with-
drawal. Cancer Res. 57, 4063–4069
15. Kim, J.W., Cho, H. S., Kim, J. H., Hur, S. Y., Kim, T. E., Lee, J.M., Kim, I. K.,
andNamkoong, S. E. (2000) AAC-11 overexpression induces invasion and
protects cervical cancer cells from apoptosis. Lab. Invest. 80, 587–594
16. Van den Berghe, L., Laurell, H., Huez, I., Zanibellato, C., Prats, H., and
Bugler, B. (2000) FIF (fibroblast growth factor-2 (FGF-2)-interacting-fac-
tor), a nuclear putatively antiapoptotic factor, interacts specifically with
FGF-2.Mol. Endocrinol. 14, 1709–1724
17. Sasaki, H., Moriyama, S., Yukiue, H., Kobayashi, Y., Nakashima, Y., Kaji,
M., Fukai, I., Kiriyama, M., Yamakawa, Y., and Fujii, Y. (2001) Expression
of the antiapoptosis gene, AAC-11, as a prognosismarker in non-small cell
lung cancer. Lung Cancer 34, 53–57
18. Clegg, N., Ferguson, C., True, L. D., Arnold, H.,Moorman, A., Quinn, J. E.,
Vessella, R. L., and Nelson, P. S. (2003) Molecular characterization of
prostatic small-cell neuroendocrine carcinoma. Prostate 55, 55–64
19. Krejci, P., Pejchalova, K., Rosenbloom, B. E., Rosenfelt, F. P., Tran, E. L.,
Laurell, H., andWilcox, W. R. (2007) The antiapoptotic protein Api5 and
its partner, highmolecular weight FGF2, are up-regulated in B cell chronic
lymphoid leukemia. J. Leukoc. Biol. 82, 1363–1364
20. Wang, Z., Liu, H., Liu, B., Ma, W., Xue, X., Chen, J., and Zhou, Q. (2010)
Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tu-
mor tissues as prognostic factors in NSCLC patients.Med. Sci. Monit. 16,
CR357–364
21. Morris, E. J.,Michaud,W.A., Ji, J. Y.,Moon,N. S., Rocco, J.W., andDyson,
N. J. (2006) Functional identification of Api5 as a suppressor of E2F-de-
pendent apoptosis in vivo. PLoS Genet. 2, e196
22. Ren, K., Zhang, W., Shi, Y., and Gong, J. (2010) Pim-2 activates API-5 to
inhibit the apoptosis of hepatocellular carcinoma cells through NF-B
pathway. Pathol. Oncol. Res. 16, 229–237
23. Rigou, P., Piddubnyak, V., Faye, A., Rain, J. C., Michel, L., Calvo, F., and
Poyet, J. L. (2009) The antiapoptotic protein AAC-11 interacts with
and regulates Acinus-mediated DNA fragmentation. EMBO J. 28,
1576–1588
24. Ahel, D., Horejsí, Z., Wiechens, N., Polo, S. E., Garcia-Wilson, E., Ahel, I.,
Flynn, H., Skehel, M., West, S. C., Jackson, S. P., Owen-Hughes, T., and
Boulton, S. J. (2009) Poly(ADP-ribose)-dependent regulation of DNA re-
pair by the chromatin remodeling enzymeALC1. Science 325, 1240–1243
25. Otwinowski, Z., andMinor,W. (1997) Processing of x-ray diffraction data
collected in oscillation mode.Methods in Enzymology 276, 307–326
26. Terwilliger, T. C., and Berendzen, J. (1999) Automated MAD and MIR
structure solution. Acta Crystallogr. D Biol. Crystallogr. 55, 849–861
27. Emsley, P., and Cowtan, K. (2004) Coot: Model-building tools for molec-
ular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132
28. Adams, P.D., Afonine, P. V., Bunkóczi, G., Chen,V. B., Davis, I.W., Echols,
N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., Mc-
Coy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C.,
Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: A
comprehensive Python-based system for macromolecular structure solu-
tion. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221
29. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of
macromolecular structures by the maximum likelihood method. Acta
Crystallogr. D Biol. Crystallogr. 53, 240–255
30. Brünger, A. T. (1992) FreeR value: Anovel statistical quantity for assessing
the accuracy of crystal structures. Nature 355, 472–475
31. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino,
R.M., Kapral, G. J., Murray, L.W., Richardson, J. S., and Richardson, D. C.
(2010) MolProbity: All-atom structure validation for macromolecular
crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21
32. Jung, W. S., Hong, C. K., Lee, S., Kim, C. S., Kim, S. J., Kim, S. I., and Rhee,
S. (2007) Structural and functional insights into intramolecular fructosyl
transfer by inulin fructotransferase. J. Biol. Chem. 282, 8414–8423
33. Dosztányi, Z., Csizmok, V., Tompa, P., and Simon, I. (2005) IUPred: Web
server for the prediction of intrinsically unstructured regions of proteins
based on estimated energy content. Bioinformatics 21, 3433–3434
34. Holm, L., and Rosenström, P. (2010) Dali server: Conservationmapping in
3D. Nucleic Acids Res. 38,W545–549
35. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) A signa-
ture motif in transcriptional co-activators mediates binding to nuclear
receptors. Nature 387, 733–736
36. Plevin, M. J., Mills, M. M., and Ikura, M. (2005) The LxxLL motif: A
multifunctional binding sequence in transcriptional regulation. Trends
Biochem. Sci. 30, 66–69
37. Choudhary, C., Kumar, C., Gnad, F., Nielsen,M. L., Rehman,M.,Walther,
T. C., Olsen, J. V., andMann, M. (2009) Lysine acetylation targets protein
complexes and co-regulates major cellular functions. Science 325,
834–840
38. Scroggins, B. T., Robzyk, K.,Wang, D., Marcu, M. G., Tsutsumi, S., Beebe,
K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., Rosen, N., and Neckers, L.
(2007) An acetylation site in the middle domain of Hsp90 regulates chap-
erone function.Mol. Cell 25, 151–159
39. Groves,M. R., and Barford, D. (1999) Topological characteristics of helical
repeat proteins. Curr. Opin. Struct. Biol. 9, 383–389
40. Tu, D., Li, W., Ye, Y., and Brunger, A. T. (2007) Structure and function of
the yeast U-box-containing ubiquitin ligase Ufd2p. Proc. Natl. Acad. Sci.
U.S.A. 104, 15599–15606
41. Vetter, I. R., Arndt, A., Kutay, U., Görlich, D., andWittinghofer, A. (1999)
Structural view of the Ran-Importin  interaction at 2.3 A resolution.Cell
97, 635–646
42. Cho, U. S., and Xu, W. (2007) Crystal structure of a protein phosphatase
2A heterotrimeric holoenzyme. Nature 445, 53–57
Structure of Apoptosis Inhibitor 5
10736 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 14 • MARCH 30, 2012
43. Goldenberg, S. J., Cascio, T. C., Shumway, S. D., Garbutt, K. C., Liu, J.,
Xiong, Y., and Zheng, N. (2004) Structure of the Cand1-Cul1-Roc1 com-
plex reveals regulatory mechanisms for the assembly of the multisubunit
cullin-dependent ubiquitin ligases. Cell 119, 517–528
44. Choi, H. J., Gross, J. C., Pokutta, S., andWeis, W. I. (2009) Interactions of
plakoglobin and -catenin with desmosomal cadherins: Basis of selective
exclusion of - and -catenin from desmosomes. J. Biol. Chem. 284,
31776–31788
45. Sampietro, J., Dahlberg, C. L., Cho, U. S., Hinds, T. R., Kimelman, D., and
Xu, W. (2006) Crystal structure of a -catenin-BCL9-Tcf4 complex.Mol.
Cell 24, 293–300
46. Xing, Y., Clements,W. K., Kimelman, D., and Xu,W. (2003) Crystal struc-
ture of a -catenin-axin complex suggests a mechanism for the -catenin
destruction complex. Genes Dev. 17, 2753–2764
47. Huber, A. H., and Weis, W. I. (2001) The structure of the -catenin-E-
cadherin complex and themolecular basis of diverse ligand recognition by
-catenin. Cell 105, 391–402
48. Schwerk, C., Prasad, J., Degenhardt, K., Erdjument-Bromage, H., White,
E., Tempst, P., Kidd, V. J.,Manley, J. L., Lahti, J.M., andReinberg, D. (2003)
ASAP, a novel protein complex involved in RNA processing and apopto-
sis.Mol. Cell Biol. 23, 2981–2990
49. Tange, T. Ø., Shibuya, T., Jurica, M. S., andMoore, M. J. (2005) Biochem-
ical analysis of the EJC reveals two new factors and a stable tetrameric
protein core. RNA 11, 1869–1883
50. Yang, X. J. (2004) Lysine acetylation and the bromodomain: A new part-
nership for signaling. Bioessays 26, 1076–1087
51. Yang, X. J., and Seto, E. (2008) Lysine acetylation: Codified cross-talk with
other post-translational modifications.Mol. Cell 31, 449–461
52. Zeng, L., and Zhou, M. M. (2002) Bromodomain: An acetyllysine binding
domain. FEBS Lett. 513, 124–128
53. Shen, H. (2009) UAP56, a key player with surprisingly diverse roles in
pre-mRNA splicing and nuclear export. BMB Rep 42, 185–188
54. Strässer, K., Masuda, S., Mason, P., Pfannstiel, J., Oppizzi, M., Rodriguez-
Navarro, S., Rondón, A. G., Aguilera, A., Struhl, K., Reed, R., and Hurt, E.
(2002) TREX is a conserved complex coupling transcription withmessen-
ger RNA export. Nature 417, 304–308
55. Le Hir, H., and Andersen, G. R. (2008) Structural insights into the exon
junction complex. Curr. Opin. Struct. Biol. 18, 112–119
56. Ma, N. F., Hu, L., Fung, J. M., Xie, D., Zheng, B. J., Chen, L., Tang, D. J., Fu,
L., Wu, Z., Chen, M., Fang, Y., and Guan, X. Y. (2008) Isolation and char-
acterization of a novel oncogene, amplified in liver cancer 1, within a
commonly amplified region at 1q21 in hepatocellular carcinoma. Hepa-
tology 47, 503–510
57. Ashkenazy, H., Erez, E., Martz, E., Pupko, T., and Ben-Tal, N. (2010) Con-
Surf 2010: Calculating evolutionary conservation in sequence and struc-
ture of proteins and nucleic acids. Nucleic Acids Res. 38,W529–533
Structure of Apoptosis Inhibitor 5
MARCH 30, 2012 • VOLUME 287 • NUMBER 14 JOURNAL OF BIOLOGICAL CHEMISTRY 10737
